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1. Colorectal cancer: epidemiology, etiology, risk and protective factors and 
chemoprevention 
 
1.1. Colorectal Cancer 
Cancer is the second leading cause of death, after cardiovascular diseases, in 
occidental countries [1]. Colorectal cancer (CRC) incidence varies considerably across 
geographical regions; however, it is one of the most common malignancies and cause of 
cancer death in developed countries [2], such as United States [3] and Europe [4]. In Europe, 
CRC is the third most common type of cancer in both men and women and the second leading 
cause of cancer related-death (Figure 1) [2].  
 
 
 
Figure 1. Estimated incidence (A) and mortality (B) of cancer in the European Union (EU25), 2006 (taken from [5]). 
 
 
 
The prevalence of CRC has been steadily increasing over the last century (Figure 2), 
possibly as a result of industrialization and changes in life style/environmental/dietary factors, 
while mortality rates have declined as a result of efficient screening and surveillance [2].  
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Figure 2. Lifetime risk of colorectal cancer in Great Britain; Cancer Research UK (taken from 
http://info.cancerresearchuk.org/cancerstats ). 
 
CRC includes malignant growths from the mucosa of the colon, rectum and appendix, 
and most tumors appear in the left side of colon and rectum (Figure 3).  
 
Figure 3. Percentage dis tribution of cases of colorectal  cancer within the large bowel , Great Britain, 2006-2008; 
Cancer Research UK, (taken from http://info.cancerresearchuk.org).  
 
CRC is traditionally divided into sporadic and hereditary forms [6]. Although there are 
some well- recognized genetic causes of CRC, the vast majority of cases (≈95%) are considered 
to be sporadic [7]. Instead, only approximately 5% of cases are associated with one of two 
genetic syndromes, namely familial adenomatous polyposis (FAP) and hereditary non-
polyposis colorectal cancer (HNPCC or Lynch syndrome). FAP is associated with an inherited 
genetic mutation in the tumor suppressor gene adenomatous polyposis coli (APC), and HNPCC 
to mutations in genes associated with DNA mismatch repair [7]. 
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1.2. Risk and protective factors 
Risk factors for CRC include age, family history and environmental and dietary factors 
[8]. In younger populations, the risk for developing CRC is very low but  the probability of 
developing CRC rises sharply with age (Figure 4) [8]. Also, a family history of CRC (particularly 
with relatives diagnosed under the age of 45 years) is associated with an increased risk of 
developing CRC [9]. Evidence from migrating populations [10] suggests a strong effect of 
environment on CRC risk [11,12].  Chronic inflammatory bowel disease (Crohn's disease and 
ulcerative colitis) is also associated with an increased risk for CRC [1]. Also, epidemiological 
studies have highlighted the role of diet and lifestyle in CRC risk: positive correlations have 
been reported for high caloric intake, high consumption of red meat (especially if burned)  and 
saturated fat, high alcohol intake as well as cigarette smoking, obesity and diabetes [8,13,14], 
and inverse correlation between CRC and the intake of fish (rich in n-3 polyunsaturated fatty 
acids), fruits and vegetables [15-18]. Studies estimate that nutritional factors are responsible 
for 70-90% of CRC cases, and that diet optimization will prevent most of them [19,20]. Other 
non dietary environmental lifestyle and supplementary factors with protective effects include 
moderate to vigorous physical activity, hormone replacement therapy in postmenopausal 
women, and the regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin 
[21,22]. 
 
Figure 4. Average number of new cases per year and age -specific incidence rates per 100,000 population; Cancer 
Research UK (taken from http://info.cancerresearchuk.org). 
 
As stated, diet and other environmental risk factors play important roles in CRC 
development [8]. However, only a small proportion of individuals exposed to those risk factors 
will develop CRC, while many individuals without those risk factors develop CRC. This suggests 
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that genetic factors also play an important role in colorectal carcinogenesis [23]. So, CRC 
development is determined by a complex interaction between genetic and specific 
environmental/life style risk factors with different degrees of involvement [23]. 
 
1.3. Colorectal carcinogenesis 
CRC results from the cumulative effect of multiple sequential genetic and epigenetic 
alterations in colorectal epithelium (multistep carcinogenesis) (Figure 5), generally acquired 
(and not inherited) [24,25]. Multiple molecular pathways appear to exist in CRC, but three 
major independent pathways have been described: the chromosomal instability pathway (CIN) 
(adenoma-carcinoma sequence) (Figure 5), which is characterized by allelic loss, a pathway 
involving microsatellite instability (MSI), and CpG island methylator phenotype (CIMP) pathway 
[26].   
 
 
 
Figure 5. Mechanisms and molecular events  that characterize the transi tion from normal epithelium to CRC (taken 
from [27]). 
 
The large majority of CRC cases develop from the CIN pathway [26], where colorectal 
polyps (also referred to as adenomas) are an intermediate step in the development of 
adenocarcinoma [28,29]. Indirect evidence suggests that adenomas may be present for 10 
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years or more before malignancy development [30,31]. Adenomas smaller than 3 mm in 
diameter are classified as having very low malignancy risk and rarely develop to malignancy 
[28]. However, adenomas are found to coexist with cancer in approximately 30% of cases 
[32,33]. So, current efforts are directed towards detection and removal of adenomas. About 
90% of total adenomas can be observed and removed by colonoscopy. Therefore, colonoscopy 
has become a part of routine clinical practice and is the method of choice for CRC screening 
and prevention [34,35]. 
 
1.4. Chemoprevention strategy 
Although the efficacy of colonoscopy (and fecal occult blood testing) in reducing CRC 
incidence and mortality is well established, there are some major pitfalls. First, the positive 
impact of colonoscopy is largely operator-dependent [36-38]. Second, colonoscopy seems to 
provide more protection against distal rather than proximal colon cancer [38-40]. So, because 
CRC prevention by colonoscopy has some limitations, chemoprevention might be an 
alternative choice for reducing the incidence of CRC [41]. Chemoprevention is the use of 
synthetic or natural compounds, in pharmacological doses, to reduce the risk of development 
or recurrence of cancer [42]. Many natural dietary compounds present in fruits and 
vegetables, including fiber, short-chain fatty acids (e.g. butyrate, which is a product of dietary 
fiber decomposition in large intestine), folate, L-methionine, selenium, vitamin D, calcium and 
phytochemicals have been isolated and their health promoting properties have been 
demonstrated [42,43].  
 
2. Butyrate in CRC 
 
Dietary fiber (particularly from cereal and whole grains [44]) is one of the most 
promising candidates for a protective role in CRC, with strong support from both 
epidemiological and experimental animal studies [45-48]. Dietary fiber exerts a protective role 
against CRC through a variety of mechanisms [42,43]. Short-chain fatty acids (SCFAs; acetate, 
propionate and butyrate) are organic acids produced in the intestinal lumen by bacterial 
fermentation of mainly undigested dietary fiber [49]. Butyrate (BT) is an important mediator in 
the observed protective effect of fermentable dietary fiber in the prevention/inhibition of 
colon carcinogenesis [50-52]. BT is the main energy source for colonocytes [53] and promotes 
growth and proliferation of normal colonic epithelial cells [54,55]. However, BT inhibits colon 
carcinogenesis (by suppressing growth of cancer cells, inducing differentiation and apoptosis 
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and inhibiting cell proliferation) [56,57]. Also, several well-designed animal models have 
demonstrated a protective effect of BT on colorectal carcinogenesis [58-63]. Moreover, there 
is an inverse relationship between the levels of BT in the human colon and the incidence of 
CRC [64], as well as an increased incidence of tumors in the distal colon, where the 
concentration of BT is lower, suggesting an inverse relationship between BT and CRC [65]. A 
role for BT in the development of CRC has been also supported by the observation of a 
downregulation of BT transporters (monocarboxylate transporter 1 (MCT1) and sodium-
coupled monocarboxylate transporter 1 (SMCT1)) in CRC, causing a reduction in BT uptake by 
colonic epithelial cells [66-68]. 
 
2.1. Mechanisms involved in the anticarcinogenic effect of BT 
The mechanism by which BT inhibits colon carcinogenesis seems to involve various 
effects on gene expression, which are mainly attributed to its capacity to act as a histone 
deacetylase inhibitor (HDACi), leading to hyperacetylation of histones [69,70]. Histone 
hyperacetylation leads to a more relaxed chromatin structure, and thus facilitates transcription 
factor access to the promoter regions of certain genes, without directly initiating gene 
transcription [71,72]. HDAC inhibitors are critical epigenetic regulators, and a new class of 
anticancer agents by virtue of their ability to arrest cell proliferation and promote cell 
differentiation or stimulate apoptosis in tumoral cells [72-74]. However, it is likely that BT has 
other intracellular targets, including alteration of DNA methylation [75], histone methylation 
[76], hyperacetylation of nonhistone proteins [77], selective inhibition of histone 
phosphorylation [78], regulation of the expression of micro-RNA (miRNA) [79,80], and 
modulation of intracellular kinase signaling [81-84]. 
More recently, it was demonstrated that BT can also elicit biologic effects on colonic 
epithelial cells without entering the cells [85]. BT is a physiologic agonist of GPR109A, a G-
protein-coupled receptor which is abundantly expressed in the apical membrane of mouse and 
human colonic epithelial cells [85]. GPR109A acts as a tumor suppressor in colon, and its 
expression is silenced in human CRC, in a mouse model of CRC and in colon cancer cell lines 
[85]. SCFAs were also reported as ligands for GPR41 and GPR43 [86-88], activating these 
receptors in a concentration-dependent and specific manner [87,89]. GPR43 has been shown 
to be present in both human and rat colon [90], and GPR43 expression is markedly reduced 
and, in some cases, completely lost in colon adenocarcinomas and in established colon cancer 
cell lines [91]. The expression pattern of GPR43 suggests that the loss of GPR43 expression is 
related to the transition from a benign to a malignant carcinoma. 
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BT influences several important processes in tumorigenesis, including cell proliferation, 
apoptosis, angiogenesis, immunosurveillance, oxidative stress and inflammation. In colon 
cancer cells, BT elicits an anticarcinogenic effect by induction of apoptosis [56,92], inhibition of 
proliferation and promotion of a more differentiated phenotype [93,94]. BT is able to block cell 
proliferation, mainly in the G1 phase of the cell cycle [95], by inducing a decreased expression 
of the proto-oncogenes c-src and c-myc [96,97] or an increase in p21Waf1/Cip1 and cyclin D 
expression [98,99], via inhibition of HDACs. However, a recent report showed that BT affects 
p21Waf1 /Cip1 gene expression via decreased expression of the miR-106b gene family [79]. BT also 
induces G2/M cell-cycle arrest [100]. Additional effects of BT on cell apoptosis involve the 
intrinsic or mitochondrial apoptotic pathway [101,102], affecting Bcl2 family proteins, e.g., 
upregulation of (pro-apoptotic) BAK and downregulation of (anti-apoptotic) BclxL [103,104]. 
However, BT can also induce extrinsic apoptosis pathway [101]. 
Angiogenesis, the formation and growth of new blood vessels from preexisting 
microvasculature, is a key stage in tumor growth, invasion, and metastasis. It has been 
suggested that BT inhibits tumor-induced angiogenesis through modulation of vascular 
endothelial growth factor (VEGF), hypoxia-inducible factor (HIF)-1α and neuropilin-1 (NRP-1) 
[105,106]. In addition, BT decreases the metastatic and invasive potential of cancer cells by 
decreasing the activity of pro-metastatic matrix metalloproteinases (MMP-2) and other 
metastasis-associated genes as well as by inducing metastasis suppressors [107-109]. 
Oxidative stress has the potential to affect a large array of carcinogenic pathways, 
because its targets, including DNA, RNA, lipids, and proteins, are involved in enhanced 
malignant transformation and proliferation of initiated cells [110]. BT inhibits oxidative stress, 
since incubation of isolated rat [111] or human [112] colonocytes with BT showed a significant 
reduction in H2O2-induced genotoxicity. BT also reduced 4-hydroxynonenal-induced 
genotoxicity in colon cells [113]. BT does not act as a free-radical scavenger due to its chemical 
structure. However, BT may act as a secondary antioxidant by affecting the levels of enzymatic 
or non-enzymatic antioxidant systems and DNA repair systems. Indeed, BT increases 
antioxidant GSH levels [46,112,114] and enhances glutathione-S-transferase [115] and catalase 
activities [116] thus reducing oxidative stress levels. Moreover, cells defective in DNA 
mismatch repair (MMR) genes generate mutations at a rate 1000-fold greater than observed in 
normal cells, being the hMLH1 (human mutL homolog 1) the most frequently MMR gene 
silenced in CRC [117], and BT was found to reduce hMLH1 promoter methylation in CRC cells 
[118], and to increase the accessibility of DNA repair enzymes to chromatin [112]. 
Inflammatory bowel disease (chronic colitis or persistent inflammation in the colon) is 
associated with a higher risk of CRC [119]. Inflammation promotes CRC development by 
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creating an inflammatory microenvironment during tumor tissue formation. One mechanism 
to explain the contribution of inflammation to carcinogenesis is oxidative stress, and 
interestingly BT inhibits oxidative stress, as shown above [111,112]. Another mechanism to 
explain the role of inflammation in cancer is the production of cytokines by inflammatory cells. 
The inflammatory and immunosuppressive cytokines and chemokines not only promote 
proliferation, angiogenesis, invasion, and metastasis but also suppress the host's immune 
system and facilitate tumor growth and CRC development [110]. Interestingly, BT has been 
shown to reduce inflammation by inhibition of nuclear factor kappa B (NF-kB) activation [120-
122] and by upregulation of peroxisome proliferator-activated receptor-ɤ (PPARɤ) [123,124]. 
Moreover, cyclooxygenase-2 (COX-2) overexpression, which plays an important role in the 
inflammation-carcinogenesis pathway of CRC, is suppressed by BT [125-127]. 
 
 
3. Absorption of BT 
 
Because many cellular effects of BT are dependent on its intracellular concentration 
(e.g. inhibition of histone deacetylases), knowledge on the mechanisms involved in its 
membrane transport seem particularly important. Absolute concentrations of BT in human 
faeces were found to range from 11 to 25 mM [128,129], and BT is preferentially absorbed in 
the proximal part of colon where the highest luminal concentration occurs [130-132]. BT is a 
weak acid (pKa=4.8), more than 90% existing in the ionized form under physiological 
conditions in the colon (pH 5.5–6.7), and requiring a transporter protein for absorption [133-
135]. Several different mechanisms for BT uptake across the apical membrane of colonocytes 
have been proposed, including simple diffusion of the undissociated form (through the lipid 
membrane (in the distal colon)) [133-135], counter-transport with bicarbonate (BT⁄HCO3
- 
exchanger) [136,137] and transport by monocarboxylate transporters [138,139]. The two 
major monocarboxylate transporters identified for BT absorption across the luminal 
membranes of colonocytes are the H+-coupled monocarboxylate transporter 1 (MCT1), a 
member of SLC16 gene family [138-140], and the Na+-coupled monocarboxylate transporter 1 
(SMCT1), a member of the SLC5 gene family [138,139,141]. The molecular identity of the non-
electrogenic pH-dependent BT/HCO3
- exchange is yet unknown [142,143]. 
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3.1. Monocarboxylate transporter 1 
The monocarboxylate transporter (MCT) family is composed by 14 members, and 
belongs to the major facilitator superfamily, being encoded by the SLC16 gene family 
(reviewed in [144]). Although being a family of 14 members, only the first four (MCT1-MCT4) 
have been demonstrated experimentally to transport monocarboxylates [145-147]. To 
function, MCT translocates a proton through the plasma membrane together with a 
monocarboxylate, by an ordered mechanism in which H+ binding is followed by 
monocarboxylate binding to the protonated transporter [148]. The monocarboxylate flux 
direction depends on the chemical gradients for H+ and monocarboxylates across the 
membrane [147]. 
The MCT1 (SLC16A1) gene was cloned in 1994 [149] and the structural gene 
organization as well as isolation and characterization of SLC16A1 promoter was then achieved 
[150]. MCT1 functional protein is composed by 500 amino acids (Figure 6), is quite well 
conserved (e.g. the protein sequences of rat and humans show 83% identity and 87% 
similarity) and is ubiquitously expressed in almost all tissues [151]. MCT1 is composed of 12 
transmembrane alpha helices (TMs) with a large loop between TMs 6 and 7 and the C and N 
termini facing the cytosol [152,153]. The N-terminus is more conserved among different MCTs 
isoforms and is believed to be more important for energy coupling, membrane insertion 
and/or correct structure maintenance, whereas the C-terminal domain may be more 
important for determination of substrate specificity and binding [154]. 
 
Figure 6. MCT1 protein diagram (taken from  [144]). 
 
MCT1 transports a variety of substrates including short-chain (C2-C5) unbranched 
aliphatic monocarboxylates (e.g. BT), and monocarboxylates with C2 or C3 substitutions 
(excluding amino/amido substitutions) (e.g. pyruvate, L-lactate, acetoacetate and β-
hydroxybutyrate) [155,156]. More hydrophobic ketoacids derived by transamination of amino 
acids may also be transported by MCT1: this includes phenylpyruvate (from phenylalanine), α-
ketoisocaproate (from leucine), α-ketoisovalerate (from valine), and α-keto-β-methylvalerate 
(from isoleucine) [144]. However, numerous drugs containing a carboxyl group in their 
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chemical structure and/or weak organic acids compounds may be potential substrates for 
MCT1. 
 
3.1.1. MCT1 regulation 
Several aspects of MCT1 regulation are poorly understood. However, it is known that 
MCT1 is regulated at various points including transcriptional and post-transcriptional 
regulation, that affect protein amounts, and regulation of transporter activity (e.g. by 
chaperone proteins). 
Studies indicate that MCT1 is regulated at various points during gene expression. The 
SLC16A1 promoter has putative binding site sequences for the transcription factors upstream 
stimulatory factor (USF) 1 and 2, NF-κB, activated protein 1 and 2 (AP1 and AP2) and 
stimulating protein-1 (Sp1) [150]. Indeed, USF1 and USF2 have been described as potential 
repressor proteins for MCT1 [157], and NF-κB pathway is involved in BT-induced MCT1 
upregulation [158], while AP2 has been associated to protein kinase C (PKC)-dependent 
stimulation of the SLC16A1 promoter [159]. Also, the co-activators peroxisome proliferator-
activated receptor gamma coactivator 1 alpha (PGC-1α) [160] and peroxisome proliferator-
activated receptor alpha (PPARα) [161,162] have been associated with MCT1 upregulation. 
MCT1 is also under post-transcriptional regulation by microRNAs. The MCT1 untranslated 
region is a target for three microRNAs (miR-29a, miR-29b, and miR-124), and recently, miR-29a 
and miR-29b have been described to silence MCT1 expression [163]. 
At the protein level, MCT1 expression varies along the human digestive tract: very low 
MCT1 expression is found in the small intestine but its expression increases in the colon with 
maximal levels in the distal segment, being confined to the upper regions of colonic crypts and 
to apical side of epithelial cells [164,165]. There is a profound diurnal rhythmicity in the 
expression of MCT1, with a maximal expression occurring before feeding phase [166]. 
Moreover, an increase in MCT1 protein levels was found in the gastrointestinal tract after 
feeding with fiber [167], and BT also induces MCT1 protein expression [158,168-170]. 
Accessory proteins also regulate MCT1 protein function. MCT1 is associated with 
CD147 (also known as basigin, EMMPRIN, OX-47 or HT7), a broadly distributed plasma 
membrane glycoprotein [171]. This ancillary protein is involved in the regulation of MCT1 
activity and localization. For example, in MCT1-transfected cells, co-transfection with CD147 
increased the expression of MCT1 in the plasma membrane [172,173]. On the other hand, 
MCT1 was also shown to be a regulator of CD147 maturation and trafficking to the plasma 
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membrane [174,175]. So, these two proteins must remain associated for MCT1 transport 
activity to be maintained (Figure 7) [172,176]. 
 
Figure 7. Monocarboxylate transporter 1 (MCT1) and CD147 predicted interaction . The interaction between CD147 
and MCT1 is  proposed to involve an L-arginine residue within transmembrane segment 8 of MCT1 and an L-glutamic 
acid residue in the transmembrane segment of CD147 (taken from [177]). 
 
The transmembrane H+ concentration gradient, or transmembrane pH differential, is a 
major factor that controls MCT1 function [156,178]. MCT1 is thus functionally coupled to 
proteins involved in acid/base regulation. Carbonic anhydrase (CA) plays a supportive role in 
pH regulation, as it clearly contributes to increased extracellular H+ concentration, thereby 
enhancing MCT1 transport activity [179]. Morever, carbonic anhydrase II, by direct binding to 
the C-terminal of MCT1 (possibly inducing an allosteric conformation change) also increases 
MCT1 transport activity [179]. Finally, Na+/HCO3
- cotransporter (NBC) and Na+/H+ exchangers 
(NHE) also enhance MCT1 transport [180]. 
Several chemical agents are known to inhibit MCT1 activity. Classical reversible 
inhibitors of MCT1 fall into four broad categories [144]: (1) Bulky or aromatic 
monocarboxylates like phenyl-pyruvate and α-cyano-4-hydroxycinnamate (CHC); (2) inhibitors 
of anion transport such as 5-nitro-2-(3-phenylpropylamino)benzoate and niflumate; (3) thiol 
(e.g. p-chloromercuribenzene sulphonate (pCMBS)), and amino (e.g. pyridoxal phosphate and 
phenylglyoxal) reagents; (4) amphiphilic compounds with widely divergent structures, like 
phytochemicals [181-183]. However, none of these MCT classical inhibitors is either MCT-
specific or MCT isoform-specific. AstraZeneca® newly developed immunomodulatory 
compounds appear to be MCT1 isoform-specific [184]. 
 
3.1.2. MCT1 in CRC pathophysiology 
The first report on MCT1 protein expression in human tumor samples described a 
decrease in MCT1 expression in colonic transition from normality to malignancy [66,185]. 
Later, evidence for MCT1 downregulation was also observed in other types of cancers 
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[66,186]. The decrease in MCT1 expression results in reduced uptake, metabolism and effects 
of BT in the colonocytes. The loss or silencing of MCT1 has been demonstrated to correlate 
with (a) transition from normality to malignancy in colonic epithelium [66], (b) deregulation of 
BT-responsive genes involved in differentiation and apoptosis [185,187] and (c) important 
metabolic switch from BT β-oxidation to glycolysis [188], with a simultaneous increase in 
GLUT1 expression [66,189] and production of high levels of glycolytic metabolites [190]. 
Furthermore, MCT1 protein is also downregulated in inflamed mucosa of inflammatory bowel 
disease patients, in animal models of inflammation, and in response to the proinflammatory 
cytokines IFN-ɤ and TNF-α [191]. Interestingly, treatment with infliximab (an anti-TNF-α 
monoclonal antibody) significantly increased MCT1 mRNA levels in inflamed colon of Crohn's 
disease patients [192]. The reduction in uptake of BT which occurs during inflammation may 
contribute to the fact that inflammatory bowel disease is associated with an elevated risk of 
CRC [191,193]. 
 
3.2. Sodium-coupled monocarboxylate transporter 1 
SLC5A8 transporter is a member of the sodium solute symporter family (SLC5). It was 
first cloned and recognized as a passive transporter by Rodriguez et al. (2002)  in the search for 
the sodium iodide symporter [194]. This transporter is encoded by the SLC5A8 gene (Figure 8) 
localized at chromosome 12q23.1 [67]. The SLC5A8 gene promoter has been also characterized 
[195]. SLC5A8 encodes a protein with 610 amino acids [196] expressed abundantly in the 
apical membrane of the ileum and colon [68,165,197,198]. In both humans and mice, SLC5A8 
protein levels are highest in distal colon, followed by proximal colon and ileum [193]. 
Figure 8. SLC5A8 gene. (A) The genomic s tructure of the SLC5A8 gene. Black boxes represent exons , and arrows 
represent the s tart and s top codons . (B) The nucleotide sequence of the SLC5A8 coding region (taken from [67]). 
 
Recently, SLC5A8 has been characterized as a Na+-coupled BT transporter [199,200]  
being thus also referred as sodium-coupled monocarboxylate transporter 1 (SMCT1) [201]. BT 
is cotransported with Na+ into the cell, following the inward electrochemical gradient for Na+ 
ions maintained by the Na+/K+-ATPase [199,200]. The transport is electrogenic, due to 
3Na+:1BT stoichiometry that results in the transfer of net positive charge into cells  [202]. The 
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substrate specificity of SMCT1 and MCT1 is very similar [144]. SMCT1 transports a variety of 
monocarboxylates such as lactate, pyruvate and short-chain fatty acids [198,199], ketone 
bodies [203], nicotinate structural analogs [204,205], pyroglutamate (amino acid derivative) 
[206] and benzoate and its derivatives (salicylate and 5-aminosalicylate) [205]. 
 
3.2.1. SMCT1 regulation 
Information on the regulation of SMCT1 expression and function in the intestine is very 
limited. It is known that ob/ob mice (an animal model of obesity) show a decrease in SMCT1 
protein levels [207], and SMCT1 is also downregulated by inflammation [193]. Studies have 
shown that SMCT1 expression is frequently silenced in aberrant crypt foci (the earliest 
detectable morphologic abnormality of the colonic epithelium), colon adenomas, colon 
cancers and colon cancer cell lines, suggesting that SMCT1 silencing is an early event in colon 
tumorigenesis [67,201]. SMCT1 is also silenced in cancers of the thyroid, head and neck, 
breast, stomach, prostate, pancreas and blood [67,208-214]. Interestingly, CRC patients often 
have chromosome 12q allelic loss, which contains the SLC5A8 gene [215,216]. So, SMCT1 was 
proposed to function as a tumor suppressor, the ability of this transporter to mediate the 
entry of BT into colonocytes underlying its potential tumor suppressor function [67,141,201]. 
Of note, combination of upregulation of matrix metalloproteinases 7 and SMCT1 
downregulation is an optimal biomarker for identifying CRC cases [217]. Also, SMTC1 activity 
was positively correlated with CRC remission and patient survival [68]. 
SMCT1 expression is decreased in the absence of gut commensal bacteria [218] and by 
TNF-α [193] and increased by the probiotic Lactobacillus plantarum [193] and by activin A (a 
member of the transforming growth factor-β (TGF-β) superfamily) [219]. Finally, SMCT1 
activity is known to be inhibited by some non-steroidal antiinflammmatory drugs (NSAIDs) 
(ibuprofen, ketoprofen, fenoprofen and naproxen, with ibuprofen being the most specific and 
potent inhibitor of SMCT1) [205], and stimulated by some other NSAIDs (diclofenac, 
meclofenamate and sulindac) [220]. 
 
4. From tumor cell metabolism to CRC therapy 
 
BT is considered to be the main energy source for colonocytes, accounting to about 
70% of total energy utilization (Figure 9) [221]. 
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Figure 9. Overview of BT metabolism (uptake and oxidation) in colonocytes . In this figure, taken from [222], BT 
uptake is represented as MCT1-mediated only, because SMCT1-mediated BT uptake in the native human intestine 
or in intestinal epi thelial cell lines  had not yet been shown. 
 
However, CRC often exhibits an altered cell metabolism when compared to normal 
colorectal tissues. More specifically, CRC shows an increase in the rate of glucose uptake, via 
an upregulation of the facilitative glucose transporters (e.g. GLUT1)  [223], an increase in the 
expression levels and activity of glycolytic enzymes and glycolysis (2- to 17- times) (Figure 10) 
[221,224,225]. As a result, CRC has a markedly enhanced rate of anaerobic glycolysis (this is 
referred as the Warburg effect - i.e. the continued use of the glycolytic metabolic pathway 
even in the presence of adequate oxygen to support mitochondrial oxidative phosphorylation), 
and rapidly convert the majority of glucose into lactate  [221,226]. CRC cells also show a 
reduction in BT uptake, which is consistent with the reduction in MCT1 and SMCT1 expression 
[221,226]. This agrees with the observation that increased intracellular glucose concentration 
(due to an increase in glucose uptake) downregulates MCT1 expression in CRC cells [227]. This 
may explain why CRC cells are less dependent on BT as energy source and, therefore, more 
reliant on glucose. 
 
Figure 10. Transport and metabolism of glucose in normal cells versus tumor cells (taken from [228]). 
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The high rate of glucose uptake associated with increased glycolytic fluxes has been 
exploited clinically for the detection of malignant tumors [229,230]. Indeed, as tumor cells are 
metabolically more active than untransformed cells, 18F-fluorodeoxyglucose (FDG) is 
preferentially taken up by tumor cells resulting in a hot spot on positron emission tomography 
(PET) imaging, thus providing a powerful diagnostic tool with a high sensitivity and specificity 
[231]. 
Additionally, the increased glycolytic metabolism in CRC provides multiple potential 
targets for treatment strategies [232]. Briefly, the potential therapeutic strategies may target 
glycolysis inhibition, that will result in cancer cell death, or promote oxidative phosphorylation 
[232]. In relation to the first possibility, glycolysis can be dampened by reducing glucose 
availability through inhibition of its uptake or by selective inhibition of glycolytic enzymes. 
Although the main controlling steps of glycolysis are glucose transporters (GLUTs) and 
hexokinases (HK) [233], experimental approaches usually yielded more than a single proposed 
rate-limiting step for inhibition of glycolysis (Figure 11) [233]. Indeed, several distinct 
components of the glycolytic pathway have been targeted for therapy development (Figure 
11) although relatively few have been carried through to in vivo experiments and even fewer 
to clinical trials [234]. Various glycolytic inhibitors with potential anticancer activity have been 
identified. Lonidamine, a derivative of indazole-3-carboxylic acid, is a specific inhibitor of 
hexokinase II and was one of the first glycolysis inhibitors to be tested in cancer therapy [235]. 
The glucose analog 2-deoxy-D-glucose (2-DG) has been most widely investigated for glucose 
metabolism targeting. 2-DG competitively inhibits glucose transport and phosphorylation by 
hexokinases [236-238]. 3-Bromopyruvate, an alkylating agent, has been demonstrated to be a 
powerful and specific antitumoral agent [239-241]. 3-Bromopyruvate inhibits cellular energetic 
metabolism, both at glycolysis and mitochondria levels, depleting the whole ATP cell factory 
[242]. Clotrimazole, an antifungal imidazole derivative, can induce detachment of glycolytic 
enzymes from mitochondria and thus inhibits glycolysis [243]. 
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Figure 11. Glycolytic enzyme targeting by anticancer drugs  (taken from [221]). 
 
Tumoral cells convert the majority of glucose into lactate, and to maintain a permissive 
intracellular pH, high glycolytic rates and ATP levels, cells must efficiently export lactate [244]. 
MCTs contribute to intracellular pH regulation by co-transporting lactate together with a 
proton [147]. MCT4 is a low-affinity/high capacity lactate transporter (Km of 20–30 mM) 
associated with the export of lactate in cells with high glycolytic rates [147] and known to be 
upregulated in cancers and in tumor cell lines [245,246]. Interestingly, oxygenated tumor cells 
(located at the vicinity of blood vessels) prefer using lactate over glucose as the primary energy 
source for oxidative metabolism [247-250]. Recently, a symbiosis between anaerobic glycolytic 
cells (that produce lactate) and aerobic oxidative tumor cells (that consume lactate) was 
demonstrated, and MCTs have been discovered to play an important role in this cycle  (Figure 
12) [250]. So, in glycolytic/hypoxic cancer cells glucose is taken up by GLUT1 and lactate is 
effluxed by MCT4, and distinctly, in oxidative/oxygenated cancer cells lactate is taken up by 
MCT1 (Figure 12) [250]. This generates a micro-system, resembling the Cori cycle between liver 
and muscle, which allows recycling products of anaerobic metabolism to sustain cancer cell 
energetics. 
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Figure 12. Model  according to which tumors  behave as metabolic symbionts . Tumor heterogeneity includes 
metabolism. At a  remote location from perfused blood vessels, hypoxic tumors cells rely on glycolysis for survival 
and proliferation. High ATP production mandatorily depends on high glucose availability and is associated with the 
release of lactate, a  process facilitated by monocarboxylate transporter 4 (MCT4). In contrast, although they also 
express glucose transporters (GLUT), oxygenated  tumor cells have a metabolic preference for lactate versus 
glucose. MCT1 is  a  transporter adapted for lactate uptake [250]. This metabolic cooperativi ty is  a  key for tumor cell 
survival under hypoxia  in vivo (taken from [234]). 
 
Thus, another strategy for targeting tumoral cell metabolism is disruption of lactate 
transporters, and in this context MCTs should be considered a promising target for anticancer 
strategy [250-252]. Importantly, promising results using in vitro and in vivo models have been 
reported, where administration of an MCTs inhibitor retarded tumor growth and rendered 
tumor cells sensitive to radiation [250], and where MCT4 silencing (with RNAi) impaired 
secretion of lactate generated through glycolysis and induced cell cycle arrest and apoptosis 
[253]. 
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The main aims of the project were to clarify the mechanisms involved in the intestinal 
transport of BT, their regulation by a variety of xeno and endobiotics, and to search for 
implications of these processes in colonic health, specifically in CRC. To accomplish this, the 
specific aims of this study were: 
 
 
CHAPTER A - Characterization of BT transport at the intestinal epithelial level 
 
- to characterize the uptake of 14C-BT by the human tumoral intestinal epithelial 
(Caco-2) cell line, and to test the effect of a series of compounds upon it; 
 
- to characterize the uptake of 14C-BT by nontransformed intestinal epithelial cell 
lines (fetal human colonic epithelial cell line (FHC) and rat intestinal epithelial cell 
line (IEC-6)), and to test the effect of a series of compounds upon it; 
 
- to investigate the possibility of 14C-BT being transported by the ATP-binding 
cassette (ABC) transporters P-glycoprotein (MDR1), multidrug resistance proteins 
(MRPs) or breast cancer resistance protein (BCRP); 
 
CHAPTER B - Modulation of BT transport and of its anticarcinogenic effect 
 
- to investigate the effect of some mineral waters and of some of their constituents 
upon uptake of 14C-BT by the tumoral intestinal epithelial (Caco-2) cell line; 
 
- to investigate the effect of several dietary polyphenols upon uptake of 14C-BT by 
the tumoral intestinal epithelial (Caco-2) cell line and to correlate this effect with 
the modulation of the anticarcinogenic effect of BT in these cells;  
 
- to investigate the effect of n-3 polyunsaturated fatty acids (PUFAs), n-6 PUFAs, 
conjugated linoleic acid (CLA) and bile salts upon uptake of 14C-BT by tumoral 
(Caco-2) and non-tumoral (IEC-6) intestinal epithelial cell lines; 
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- to investigate the effect of the primary bile acid chenodeoxycholic acid (CDCA) 
upon uptake of 14C-BT by tumoral (Caco-2) and non-tumoral (IEC-6) intestinal 
epithelial cell lines and to correlate this effect with the modulation of the 
anticarcinogenic effect of BT in these cells;  
 
- to investigate the effect of oxidative stress upon uptake of 14C-BT by tumoral 
(Caco-2) and non-tumoral (IEC-6) intestinal epithelial cell lines; 
 
 
CHAPTER C - Cancer cell metabolism 
 
- to investigate the effect of cannabinoids upon 3H-2-deoxy-D-glucose (3H-DG) 
uptake  by the tumoral intestinal epithelial (Caco-2) cell line; 
 
- to investigate the effect of clotrimazole in a tumoral intestinal epithelial (Caco-2) 
cell line, to compare it with the effect in a non-tumoral intestinal epithelial cell line 
(IEC-6 cells), and to investigate inhibition of energy substrate uptake as a 
mechanism contributing to its anticarcinogenic effect. 
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Characterization of BT transport at the intestinal epithelial level 
 
 
I- Modulation of butyrate transport in Caco-2 cells 
Naunyn Schmiedebergs Arch Pharmacol. 2009;379(4):325-36 
(doi: 10.1007/s00210-008-0372-x) 
IF: 2.500 
 
 
II- Characterization of butyrate uptake by nontransformed intestinal epithelial cell lines 
J Membr Biol. 2011;240(1):35-46 
(doi: 10.1007/s00232-011-9340-3)  
IF: 1.630 
 
 
III - The short-chain fatty acid butyrate is a substrate of breast cancer resistance protein 
Am J Physiol Cell Physiol. 2011;301(5):C984-94 
(doi: 10.1152/ajpcell.00146.2011)  
IF: 3.817 
Comment in: Am J Physiol Cell Physiol. 2011;301(5):C977-79 
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Modulation of BT transport and of its anticarcinogenic effect 
 
 
IV - Effect of some natural mineral waters in nutrient uptake by Caco-2 cells 
Int J Vitam Nutr Res. 2010;80(2):131-43  
(doi: 10.1024/0300-9831/a000013) 
IF: 0.740 
 
 
V - In vitro studies on the inhibition of colon cancer by butyrate and polyphenolic compounds 
Nutr Cancer. 2011;63(2):282-94 
(doi: 10.1080/01635581.2011.523166) 
IF: 2.553 
 
 
VI - Effect of polyunsaturated fatty acids and bile salts on butyrate uptake by intestinal 
epithelial cells.  
in: Schulz MA, editor. CACO-2 Cells and Their Uses. Hauppauge NY, 
USA: Nova Science Publishers Inc., pp. 89-99. 
 
 
VII - Inhibition of butyrate uptake by the primary bile salt chenodeoxycholic acid in intestinal 
epithelial cells 
J Cell Biochem. 2012; 113(9):2937-47  
(doi: 10.1002/jcb.24172) 
IF: 3.122 
 
 
VIII - The effect of oxidative stress on the intestinal epithelial uptake of butyrate 
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ABSTRACT 
 
Our aim was to investigate the effect of n-3 PUFAs (docosahexaenoic acid (DHA) and 
eicosapentaenoic acid (EPA)), n-6 PUFAs (linoleic acid (LA), γ-linolenic acid (LNA) and 
arachidonic acid (AA)), conjugated linoleic acid (CLA) and the bile salts d eoxycholic acid 
(DCA) and taurodeoxycholic acid (TDCA) upon uptake of 
14
C-butyrate (
14
C-BT) by intestinal 
epithelial cells. 
Caco-2 cells were exposed to LA, LNA, AA, DHA, EPA, CLA and DCA (100 µM) for 1 to 
7 days. The only significant effects were slight (7-18%) increases in 
14
C-BT uptake found with 
EPA, CLA, AA and DCA. IEC-6 cells were exposed to LA, LNA, AA, DHA, EPA, CLA, DCA 
and TDCA (100 µM) for 2 days. LNA, EPA, CLA and DHA caused small (9-16%) decreases in 
14
C-BT uptake. For CLA, this effect was associated with a decrease in cellular viab ility.  
A discrete interference of n-3 and n -6 PUFAs, CLA and bile acids with the apical uptake of 
BT was observed. 
 
Keywords: bile salts; butyrate uptake; Caco-2 cells; IEC-6 cells; polyunsaturated fatty acids 
 
 
INTRODUCTION 
 
Colorectal cancer (CRC) is one of the most common solid tumours worldwide, being the second 
leading cause of cancer death among men and women combined in the United States, Australia and 
Europe, and a major problem in many other countries. The causes of CRC are multifactorial, but an 
association between reduced risk of CRC and a diet h igh in fruit, vegetables and fiber has been well 
established in epidemiological studies (Martínez et al. 2008). 
Butyrate (BT), a short-chain fatty acid produced by anaerobic bacterial fermentation of dietary 
fibre within the human colon, plays a key role in colonic epithelium homeostasis. One of the 
proposed beneficial effects of BT on human colonic health is the prevention/inhibition of colon 
carcinogenesis (Hamer et al. 2008). Many epidemiological studies show an inverse relationship 
between dietary fibre intake and the incidence of CRC (Martínez et al. 2008), and exposure of many 
colon tumour cell lines to BT leads to anticarcinogenic effects by induction of cell differentiation 
and apoptosis and by inhibition of proliferation (Heerdt et al.1994; Hague et al. 1995). At the 
molecular level, the anticarcinogenic effect of BT is considered to depend on regulation of gene 
expression, which is mainly attributed to its inhibition of histone deacetylase, resulting in 
hyperacetylation of histones and enhancement of the accessibility of transcription factors to 
nucleosomal DNA (Heerdt et al.1994; Hague et al. 1995).  
BT is transported into colonic epithelial cells by two specific carrier-mediated transport systems, 
the monocarboxylate transporter 1 (MCT1) and the sodium monocarboxylate transporter 1 (SMCT1) 
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(Gupta et al. 2006; Morris and Felmlee 2008). Interestingly enough, both MCT1 and SMCT1 were 
recently proposed to function as tumour suppressors (Cuff et al. 2005; Gupta et al. 2006). So, 
interference with either MCT1- and SMCT1-mediated transport of BT into colonocytes will 
obviously have a major impact in the context of colon carcinogenesis. In this context, MCT1-
mediated transport at the intestinal level is known to be up-regulated by its substrate, BT (Cuff et al. 
2002), enhanced by leptin (Buyse et al. 2002), phorbol 12-myristate 13-acetate (Alrefai et al. 2004), 
caffeine and acetylsalicylic acid (Gonçalves et al. 2009), and inhibited by enteropathogenic E. coli 
(Borthakur et al. 2006), interferon-, tumour necrosis factor-  (Thibault et al. 2007), theophylline, 
tetrahydrocannabinol, MDMA (ecstasy), acetaldehyde and indomethac in (Gonçalves et al. 2009), 
and by some polyphenols (Konishi et al. 2003; Vaidyanathan and Walle 2003; Wang and Morris 
2007; Shim et al. 2007). 
n-3 (n-3) and n-6 (n-6) polyunsaturated fatty acids (PUFAs) are essential fatty acids necessary 
for human health. The most widely studied effects of PUFAs are those related to eicosanoid 
biosynthesis and function. In general terms, eicosanoids derived from n-6 PUFAs have pro-
inflammatory whereas those derived from n-3 precursors have anti-inflammatory effects. Likewise, 
eicosanoids derived from these two series have opposing effects in cancer cell growth, invasion, and 
angiogenesis (Berquin et al. 2008; Chapkin et al. 2008). More specifically, in relation to CRC, and 
from a dietary perspective, a growing body of experimental, epidemiological and clinical evidence 
supports the contention that fish oil and its bioactive food components (n−3 PUFAs (eg. 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) are important in suppressing CRC 
(although several clinical trials and epidemiological studies are inconsistent), and that the opposite 
effect is observed with n-6 PUFAs (eg., linoleic acid (LA) and arachidonic acid (AA)), which are 
found in meat and vegetable oils (Berquin et al. 2008; Chapkin et al. 2008). 
Conjugated linoleic acid (CLA) is a collective term for isomers of LA that have conjugated 
double bonds. CLA has been shown to have a number of health promoting actions, including an in 
vitro and in vivo anticarcinogenic effect. Among the several mechanisms proposed to be involved in 
its anticarcinogenic effect are alteration of lipid peroxidation, tissue fatty acid composition, 
eicosanoid metabolism and gene expression (Kelley et al. 2007). 
On the other hand, secondary (unconjugated) bile acids, including deoxycholic acid (DCA), but 
not primary bile acids, have been shown to be tumour promoters, both in vitro and in animal studies 
(Reddy et al. 1977; Mahmoud et al. 1999). Moreover, raised levels of secondary bile acids have 
been reported in patients with adenomatous polyps and colon cancer (Reddy and Wynder 1977; 
Imray et al. 1992). Their mechanism of action is still poorly understood, although PKC, MAP 
kinases and NFκB have been identified as molecular targets (Huang et al. 1992; Pongracz et al. 
1995; Payne et al. 2007). 
Interestingly enough, the effects of BT and either PUFA (Hofmanová et al. 2005, 2009), CLA 
(Nichenametla et al. 2004), or bile acids (McMillan et al. 2000; Rosignoli et al. 2008) upon colonic 
epithelial cell population may be mutually influenced. So, the aim of this study was to investigate the 
hypothesis that interference with the apical uptake of BT may be one of the mechanisms contributing 
to the effect of n-3 PUFA, n-6 PUFA, CLA and bile acids upon CRC carcinogenesis. For this, we 
investigated the effect of n-3 PUFAs (DHA and EPA), n-6 PUFAs (LA, γ-linolenic acid (LNA) and 
AA), CLA, the unconjugated bile acid DCA and the conjugated bile acid taurodeoxycholic acid 
(TCDA) upon uptake of 
14
C-BT by a human colonic adenocarcinoma cell line (Caco-cells) and by a 
rat small intestinal epithelial cell line (IEC-6 cells). Caco-2 cells derive from a human colon 
adenocarcinoma, but when fully differentiated they form a polarized monolayer of cells expressing a 
combination of colonocyte and enterocyte phenotypes (Sambuy et al. 2005). On the other hand, IEC-
6 cells were established from crypt of rat intestinal cells, but when grown in post-confluent culture, 
they develop structural changes and differentiation from a crypt cell- like to an enterocyte-like 
phenotype (Wood et al. 2003). Comparison between the effect of these compounds upon BT uptake 
in carcinogenic and noncarcinogenic cell lines seemed interesting in the context of the distinct effect 
of BT in these cells (Hamer et al. 2008). 
 
VI - Effect of polyunsaturated fatty acids and bile salts on butyrate uptake by intestinal 
epithelial cells 
98 
 
 
MATERIALS AND METHODS 
 
 
Caco-2 Cell Culture 
 
The Caco-2 cell line was obtained from the Deutsche Sammlung von Mikroorganismen and 
Zellkulturen (Braunschweig, Germany) and was used between passage number 51-64. The cells 
were maintained in a humidified atmosphere of 5% CO2-95% air and were grown in Minimum 
Essential Medium (Sigma, St. Louis, MO, USA) containing 5.55 mM glucose and supplemented 
with 15% fetal calf serum, 25 mM HEPES, 100 units/ml penic illin, 100 µg/ml streptomycin and 0.25 
µg/ml amphotericin B (all from Sigma). Culture medium was changed every 2- 3 days and the 
culture was split every 7 days. For sub-culturing, the cells were removed enzymatically (0.25% 
trypsin-EDTA, 5 min, 37°C), split 1:3, and sub-cultured in plastic culture dishes (21-cm
2
;  60 mm; 
Corning Costar, Corning, NY, USA). For uptake studies, Caco-2 cells were seeded on 24-well 
plastic cell culture clusters (2-cm
2
;  16 mm; Corning Costar), and 
14
C-BT uptake experiments were 
performed 7 days after the initial seeding. For 24 h before the experiments, the cell medium was 
made free of fetal calf serum. 
 
 
IEC-6 Cell Culture 
 
The IEC-6 cell line was obtained from Deutsche Sammlung von Mikroorganismen und 
Zellkulturen (ACC-111, Braunschweig, Germany) and was used between passage number 35-37. 
The cells were maintained in a humidif ied atmosphere of 5% CO2-95% air and were cultured in 
Dulbecco’s Modified Eagle’s Medium:RPMI 1640 medium (1:1), supplemented with 10% fetal 
bovine serum, 0.1 U/ml insulin, 5.96 g HEPES, 2.2 g NaHCO3, 100 units/ml penicillin, 100 µg/ml 
streptomycin and 0.25 µg/ml amphotericin B (all from Sigma). Culture medium was changed every 
2 to 3 days and the culture was split every 7 days. For sub-culturing, the cells were removed 
enzymatically (0.05% trypsin-EDTA, 5 min, 37°C), split 1:3, and sub-cultured in plastic culture 
dishes (21 cm
2
; ∅ 60 mm; Corning Costar, Corning, NY, USA). For uptake studies, IEC-6 cells were 
seeded on 24-well plastic cell culture clusters (2 cm
2
 ∅ 16 mm; Corning Costar), and 14C-BT uptake 
experiments were performed 9 days after the initial seeding (90-100% confluence). For 24 h before 
the experiments, the cell medium was made free of fetal calf serum and insulin.  
 
 
Determination of 14C-BT uptake by Caco-2 and IEC-6 Cells 
 
The uptake experiments were performed with Caco-2 and IEC-6 cells incubated in glucose-free 
Krebs buffer (containing, in mM: 125 NaCl, 4.8 KCl, 1.2 MgSO4, 1.2 CaCl2, 25 NaHCO3, 1.6 
KH2PO4, 0.4 K2HPO4, and 20 MES (pH 6.5)). Initially, the culture medium was aspirated and the 
cells were washed twice with 0.5 ml buffer at 37°C. Then, uptake was initiated by the addition of 0.3 
ml medium at 37°C containing 
14
C-BT 10 µM. Incubation was stopped after 3 min by removing the 
incubation medium, placing the cells on ice and rinsing the cells with 0.5 ml ice-cold buffer. The 
cells were then solubilised with 0.3 ml 0.1% (v/v) Triton X-100 (in 5 mM Tris.HCl, pH 7.4), and 
placed at 37°C overnight. Radioactivity in the cells was measured by liquid scintillation counting.  
 
Treatment of the Cells with Compounds 
 
The effect of compounds on 
14
C-BT uptake was tested by cultivating cells in culture medium 
containing these compounds (or the respective solvent) for 1, 2, 3 or 7 days. The medium was 
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renewed daily, and the end of the treatment period was day 7 and 9 of Caco-2 and IEC-6 cell culture, 
respectively. 
 
 
Determination of Cell Viability 
 
To test whether the compounds affected cellular viability, the MTT (3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) assay was performed. In brief, cells were treated 
with the compounds as described above, and at the end of that period, the MTT assay was done as 
described elsewhere (Gonçalves et al. 2009). 
 
 
Protein Determination 
 
The protein content of cell monolayers was determined as described elsewhere (Bradford 1976), 
using human serum albumin as standard. 
 
 
Calculation and Statistics 
 
Arithmetic means are given with SEM, and geometric means are given with 95% confidence 
limits. Statistical signif icance of the difference between two groups was evaluated by the Student’s t-
test. Differences were considered to be significant when P<0.05. 
 
 
Materials 
 
14
C-BT (n-butyric acid, sodium salt, [1-
14
C]; specific activity 30-60 mCi/mmol (Biotrend 
Chemikalien GmbH, Köln, Germany); MES (2-[N-morpholino]ethanesulfonic acid) hydrate), 
arachidonic acid, docosahexaenoic acid, linoleic acid, γ-linolenic acid, eicosapentahenoic acid, 
conjugated linoleic acid (mixture of cis- and trans-9,11- and -10,12-octadecadienoic acids), 
deoxycholic acid, MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide), 
taurodeoxycholic acid, trypsin-EDTA solution (Sigma, St. Louis, MO, USA); DMSO 
(dimethylsulfoxide),  triton X-100 (Merck, Darmstadt, Germany); fetal calf serum (Invitrogen 
Corporation, Carlsbad, CA, USA). 
Drugs to be tested were dissolved in ethanol or DMSO, the final concentration of the solvents 
being 1% in the culture media. Controls were run in the presence of the solvent. 
 
 
RESULTS 
 
Previously, our group have shown that 
14
C-BT apical uptake in Caco-2 and IEC-6 cells was 
found to be linear with time for up to 3 min of incubation (Gonçalves et al. 2009, 2010). So, in the 
present work, cells were incubated with 
14
C-BT for 3 min, in order to determine initial rates of 
uptake. 
 
 
Effect of Pufas and Bile Acids on 14C-BT Apical uptake by Caco-2 Cells 
 
The effect of several distinct PUFAs on 
14
C-BT apical uptake by Caco-2 cells was investigated 
in the first series of experiments. For this, 100 µM of each fatty acid was tested over different 
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periods (1, 2, 3 and 7 days). Of the fatty acids tested, LA, LNA acid and DHA were devoid of 
signif icant effect (results not shown; n=6-9). However, AA, EPA and CLA caused small but 
signif icant increases in 
14
C-BT uptake at some of the time points analysed (Fig. 1A). 
In the next series of experiments, we further investigated the effect of AA and EPA, by 
characterizing its concentration-dependency. When tested for 2 days, and contrary to what was 
found with 100 µM, higher concentrations of AA and EPA decreased uptake of 
14
C-BT (1 mM of 
AA or EPA reduced uptake by 20%; Fig. 1B). This decrease was associated with a decrease in 
cellular viability (to 65.6±1.7 and 78.6±0.8% of control, respectively; n=10). Interestingly enough, 
treatment with AA (300 µM) for 7 days, which caused no decrease in 
14
C-BT uptake (Fig. 1B), was 
associated with a 24.3±6.6% increase in Caco-2 viability (n=10). None of these treatments (1 mM of 
AA or EPA for 2 days or 300 µM AA for 7 days) affected Caco-2 cell proliferation (results not 
shown). 
The effect of the bile acid DCA (100 µM) was also investigated. Apart from a small increase 
found after 2 days of treatment (to 109.4±2.5% of control; n=9), DCA was devoid of significant 
effect on 
14
C-BT uptake (results not shown). 
 
 
Figure 1. Effect of PUFA on 14C-BT uptake by Caco-2 cells. A. Time-dependence of the effect of PUFAs on the 
apical uptake of 14C-BT. Initial rates of uptake were determined in Caco-2 cells incubated for 3 min with 10 µM 14C-
BT after treatment for 1, 2, 3 or 7 days with arachidonic acid 100 µM (AA; n=9), eicosapentaenoic acid 100 µM 
(EPA; n=9-15) or conjugated linoleic acid 100 µM (CLA; n=9-13); B. Concentration-dependency of the effect of 
PUFAs on the apical uptake of 14C-BT. Initial rates of uptake were determined in Caco-2 cells incubated for 3 min 
with 10 µM 14C-BT after treatment for 2 days with increasing concentrations of arachidonic acid or eicosapentaenoic 
acid (AA - 2 days and EPA - 2 days, respectively; n=9) or after treatment for 7 days with increasing concentrations of 
arachidonic acid (AA; n=7-9). Shown are arithmetic means±SEM. * significantly different from control.  
Effect of Pufas and Bile Acids on 14C-BT Apical uptake by IEC-6 Cells 
 
We then investigated the effect of distinct PUFAs on 
14
C-BT uptake by IEC-6 cells. For this, 
IEC-6 cells were treated with 100 µM of each fatty acid for 2 days. Of the compounds tested, LA 
and AA were devoid of significant effect (results not shown; n=9). On the other hand, LNA, EPA, 
CLA and DHA caused small (9-16%) but significant decreases in 
14
C-BT uptake (Fig. 2A). The 
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effect of LNA and EPA upon 
14
C-BT uptake was found to be concentration-dependent, but this was 
not observed with DHA (Fig. 2B).  
 
 
Figure 2. Effect of PUFAs on the apical uptake of 14C-BT by IEC-6 cells. A. Initial rates of uptake were determined 
in IEC-6 cells incubated for 3 min with 10 µM 14C-BT after treatment for 2 days with γ-linolenic acid 100 µM (LNA; 
n=6), eicosapentaenoic acid 100 µM (EPA; n=9), conjugated linoleic acid 100 µM (CLA; n=9), or docosaenoic acid 
(DHA; n=9); B. Concentration-dependency of the effect of PUFAs on the apical uptake of 14C-BT. Initial rates of 
uptake were determined in IEC-6 cells incubated for 3 min with 10 µM 14C-BT after treatment for 2 days with 
increasing concentrations of γ-linolenic acid (LNA; n=6-9), eicosapentaenoic acid (EPA; n=9) or docosahexaenoic 
acid (DHA; n=3-9). Shown are arithmetic means±SEM. * significantly different from control. 
Interestingly enough, the inhibitory effect of 100 µM LNA, EPA and DHA was not associated with a 
decrease in cellular viability, as these compounds increased cellular viability (by 14.8±1.1, 21.8±1.1 
and 21.9±2.4%, respectively; n=8-9). For CLA, however, the decrease in 
14
C-BT uptake was 
associated with a similar decrease in cell viability (to 89.7±0.4% of control; n=8). 
Finally, the effect of a 2-day exposure to the bile acids DCA and TCDA (100 µM) was also 
investigated. None of the compounds affected 
14
C-BT uptake by IEC-6 cells (results not shown). 
 
 
CONCLUSION 
 
The majority of studies in the literature concerning the effects of BT, PUFAs, CLA and bile 
acids in colon carcinogenesis have considered these dietary factors individually. In vivo, however, 
they are commonly present together in the colon and so they may influence each other’s actions 
directly or indirectly. For this reason, we decided to test the effect of n-3 PUFAs (DHA and EPA), n-
6 PUFAs (LA, LNA and AA), CLA and the bile acids DCA and TDCA upon uptake of 
14
C-BT by a 
human colonic adenocarcinoma (Caco-2) cell line and by a rat small intestinal epithelial (IEC-6) cell 
line. BT plays an essential role in the maintenance of colonic tissue homeostasis, and one of its 
proposed beneficial effects is the prevention/inhibition of colon carcinogenesis (Heerdt et al. 1994; 
Hague et al. 1995). So, understanding of the regulation of its absorption by the colon mucosa 
appears to be particularly important in the context of carcinogenesis. 
Exposure of Caco-2 cells (from 1 to 7 days) to LA, LNA and DHA (100 µM) did not affect 
14
C-
BT uptake. In contrast, exposure to 100 µM EPA and DCA (for 2 days), CLA (for 3 days) or AA 
(for 2 and 7 days) caused small (7-18%) but significant increases in 
14
C-BT uptake. Treatment of the 
VI - Effect of polyunsaturated fatty acids and bile salts on butyrate uptake by intestinal 
epithelial cells 
102 
 
cells for 2 days with higher concentrations of either AA or EPA (1000 µM) caused a 20% decrease 
in 
14
C-BT uptake, which was however associated with a parallel decrease in cellular viability. These 
latter results suggest that the reduction of 
14
C-BT uptake found with the higher concentrations of 
either AA or EPA is related to cell death. Further support for this conclusion was the observation 
that treatment with a high concentration of AA (300 µM) for 7 days did not affect 
14
C-BT uptake, 
and was associated with a 25% increase in Caco-2 viability.  
Exposure of IEC-6 cells for 2 days to LA, AA, DCA and TDCA (100 µM) did not affect 
14
C-BT 
uptake. In contrast, exposure to LNA, EPA, CLA or DHA (100 µM) caused small (9-16%) but 
signif icant decreases in 
14
C-BT uptake. The decrease in 
14
C-BT uptake obtained with CLA (100 µM) 
was associated with a parallel decrease in cellular viability. However, LNA, EPA and DHA 
decreased 
14
C-BT uptake while increasing cellular viability.  
In summary, 
14
C-BT uptake is modestly modulated by some PUFA and bile salts, independently 
of an effect on cell viability. In Caco-2 cells, EPA, AA, CLA and DCA (100 µM) increased uptake, 
and in IEC-6 cells LNA, EPA and DHA (100 µM) decreased it. 
In Caco-2 cells, 
14
C-BT uptake was slightly increased by compounds possessing either 
anticarcinogenic (EPA, CLA) or carcinogenic (AA, DCA) activity against CRC. The same was 
observed in IEC-6 cells, in which 
14
C-BT uptake was slightly decreased by compounds possessing 
either anticarcinogenic (EPA, DHA) or carcinogenic (LNA) activity against CRC. This strongly 
suggests that modulation of 
14
C-BT uptake is not involved in the effect of these compounds on CRC.  
In other words, given the anticarcinogenic effect of BT in CRC cells, the increase in 
14
C-BT uptake 
in Caco-2 cells caused by EPA and CLA can be one of the mechanisms contributing to their 
anticarcinogenic effect against CRC, but cannot contribute to the carcinogenic effect of AA and 
DCA. On the other hand, in IEC-6 cells, the decrease in 
14
C-BT uptake observed with LNA can 
contribute to the carcinogenic effect of this PUFA in relation to CRC, but cannot contribute to the 
anticarcinogenic effect of EPA and DHA. 
We conclude that a discrete interference of n-3 and n-6 PUFAs, CLA and bile acids with the 
apical uptake of BT was observed. So, this does not seem to be one of the main mechanisms 
involved in the recognized role that these compounds have in colon carcinogenesis.  
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The effect of oxidative stress upon the intestinal epithelial uptake of butyrate 
 
Pedro Gonçalves, Inês Gregório, Telmo A. Catarino, Fátima Martel* 
Department of Biochemistry (U38-FCT), Faculty of Medicine, University of Porto, Porto, Portugal  
 
ABSTRACT  
Our aim was to investigate the effect of oxidative stress upon butyrate (BT) uptake at the intestinal epithelial level. For t his, IEC-6 
cells were treated with tert-butylhydroperoxide 3000 µM (tBOOH), which increased levels of oxidative stress biomarkers, while 
maintaining cellular viability. The effect of tBOOH upon uptake of 14C-BT (10 µM) can be summarized as follows: (a) it caused a 
reduction in the intracellular accumulation of 14C-BT over time, (b) it strongly reduced total 14C-BT uptake but did not affect Na+-
independent uptake of 14C-BT, and (c) it did not affect the kinetics of 14C-BT uptake at 37°C, but increased uptake at 4°C. Moreover, 
tBOOH increased the efflux of 14C-BT not mediated by breast cancer resistance protein. We thus conclude that tBOOH strongly 
inhibits Na+-coupled monocarboxylate cotransporter 1 (SMCT1)-mediated, but not H+-coupled monocarboxylate transporter (MCT1)-
mediated BT uptake; moreover, it increases uptake and efflux of BT by passive diffusion. tBOOH did not affect the mRNA expression 
levels of MCT1 and SMCT1 nor their cell membrane insertion. Rather, its effect was dependent on extracellular signal regulated 
kinase 1/2 (ERK 1/2) and protein tyrosine kinase (PTK) activation and on the generation of ROS by NADPH and xanthine o xidases  
and was partially prevented by the polyphenols quercetin and resveratrol. In conclusion, tBOOH is an effective inhibitor of SMCT1-
mediated BT transport in non-tumoral intestinal epithelial cells. Given the important role played by BT in the intestine, this mechanism 
may contribute to the procarcinogenic and proinflammatory effect of oxidative stress at this level. 
Keywords: 
IEC-6 cells; tert-butylhydroperoxide; butyrate uptake; SMCT1; polyphenols 
 
List of abbreviations: 
BCRP- BCRP- breast cancer resistance protein;  BT- butyrate;  ERK 1/2- extracellular signal regulated kinase 1/2; GK - glucose-Krebs;  GPx - total 
glutathione;  GSH – reduced glutathione;  GSSG - oxidized glutathione;  LDH - lactate dehydrogenase;  MAPK- mitogen-activated protein kinase;  
MCT1- monocarboxylate transporter 1;  MTT- 3-{4,5-dimethyl-2-thiazolyl}-2,5-diphenyl-2H-tetrazolium bromide;  PTK- protein tyrosine kinases;  
QRT-PCR – real-time quantitative reverse transcription polymerase chain reaction; ROS- reactive oxygen species; SMCT1- sodium-coupled 
monocarboxylate cotransporter 1; SRB- sulforhodamine B;  TBARS - thiobarbituric acid reactive substances;  tBOOH – tert-butylhydroperoxide 
 
 
1. Introduction 
Reactive oxygen species (ROS) are naturally produced as a 
result of oxygen metabolism. Under physiological conditions, the 
burden of ROS production is largely neutralized by an intricate 
antioxidant defense system (Wojcik et al., 2010).  Increased ROS 
level, also known as oxidative stress, is a result of either increased 
ROS generation and/or a loss of antioxidant defense mechanisms 
(Khandrika et al., 2009). A major consequence of oxidative stress 
is damage of tissue via direct oxidation of nucleic acid bases, lipids 
and proteins, but also via profound alterations in signal 
transduction pathways, which can severely compromise cellular 
functions (Okayama, 2005). Not surprisingly, it is associated with 
numerous pathologies, from atherosclerosis to inflammation and 
cancer (Halliwell, 2001; Klaunig and Kamendulis, 2004; Stocker 
and Keaney, 2004). 
 The gastrointestinal tract is a major target for oxidative stress 
damage due to constant exposure of ROS generated by a large 
variety of xenobiotics, endogenous toxic substances (e.g. bile 
acids), as well as microbes and their products (Ames, 1983). 
Interestingly, the etiology of many gastrointestinal tract diseases, 
such as colon cancer or inflammatory bowel disease, is associated 
with an imbalance in the cellular redox system leading to increased 
levels of ROS (Acharya et al., 2010; Almenier et al.,  2012; Seril et 
al., 2003).  The effect of oxidative stress on membrane transport 
mechanisms at the intestinal level remains, however, poorly 
understood.  
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Butyrate (BT) a product of intestinal flora fermentation of 
dietary fibre, plays a key role in colonic epithelium homeostasis, 
by having multiple regulatory roles at that level, including: being 
the main energy source for colonocytes; promotion of growth and 
proliferation of normal colonic epithelial cells; inhibition of colon 
carcinogenesis; inhibition of colon inflammation; and inhibition of 
oxidative stress (Hamer et al., 2008; Wong et al., 2006). BT is  
transported into colonic epithelial cells by two specific carrier-
mediated transport systems, the electroneutral H+-coupled 
monocarboxylate transporter 1 (MCT1) and the Na+-coupled 
monocarboxylate cotransporter (SMCT1) (Gupta et al., 2006). 
MCT1 (Cuff et al., 2005) and SMCT1 (Gupta et al., 2006) were 
recently proposed to function as tumor suppressors, most probably 
due to their ability to mediate the entry of BT into colonic 
epithelial cells. Therefore, factors that interfere with BT uptake 
into colonic epithelial cells are potentially detrimental to intestinal 
health and integrity by promoting oxidative stress, inflammation 
and colorectal cancer (Hamer et al., 2008; Wong et al., 2006). 
Several studies have demonstrated that ROS can interfere with 
protein, including membrane transporters, activity (Akram et al., 
2006; Kumar et al.,  2007). However, nothing is  known concerning 
the effect of oxidative stress upon the intestinal absorption of BT. 
So, the aim of this work was to investigate the effect of oxidative 
stress on 14C-BT uptake by IEC-6 cells. IEC-6 cells are a 
nontumoral rat intestinal epithelial cell line (Wood et al., 2003). 
Oxidative stress was generated with tert-butylhydroperoxide 
(tBOOH), a useful model compound to study mechanisms of 
oxidative stress injury (Deiana et al., 2010; Garcia-Cohen et al.,  
2000; Griendling et al., 2000; Tupe and Agte, 2010). 
 
2. Materials and Methods 
 
2.1. IEC-6 and Caco-2 cell culture 
 
The IEC-6 and Caco-2 cell lines were obtained from the 
Deutsche Sammlung von Mikroorganismen und Zellkulturen 
(Braunschweig, Germany) and were used between passages  
numbers 18-37 (IEC-6 cells) and 40-43 (Caco-2 cells). The cells  
were maintained in a humidified atmosphere of 5% CO2-95% air. 
IEC-6 cells were cultured in Dulbecco’s Modified Eagle’s  
Medium:RPMI 1640 medium (1:1), supplemented with 10% fetal 
bovine serum, 0.1 U/ml insulin, 5.96 g HEPES, 2.2 g NaHCO3, 
100 units/ml penicillin, 100 µg/ml streptomycin and 0.25 µg/ml 
amphotericin B (all from Sigma, St. Louis, MI, USA). Caco-2 cells  
were cultured in Minimum Essential Medium containing 5.55 mM 
glucose and supplemented with 15% fetal calf serum, 25 mM 
HEPES, 100 units/ml penicillin, 100 µg/ml streptomycin and 0.25 
µg/ml amphotericin B (all from Sigma). Culture medium was 
changed every 2-3 days and the culture was split every 7 days. For 
subculturing, the cells were removed enzymatically (0.25% 
trypsin-EDTA, 5 min, 37°C), split 1:3, and subcultured in plastic 
culture dishes (21-cm2;   60 mm; Corning Costar, Corning, NY, 
USA). For determination of cell viability, measurement of 
glutathione levels and 14C-BT uptake studies, cells were seeded on 
24-well plastic cell culture clusters (1.9 cm2; Ø 15.4 mm; TPP®, 
Trasadingen, Switzerland), and the experiments were performed 8-
9 days after the initial seeding. For measurement of lipid 
peroxidation (TBARS assay) and protein carbonyl groups, cells 
were seeded on 12-well plastic cells culture clusters (3.9 cm2; Ø 
21.4 mm; TPP®) and the experiments were performed 8-9 days 
after the initial seeding.  
 
2.2. Treatment of cells with tert-butylhydroperoxide (tBOOH) 
 
Before each experiment, the cell culture medium was removed 
and the wells were washed with Glucose-Krebs buffer at 37°C, 
containing in mM: 125 NaCl, 4.8 KCl, 1.2 MgSO4, 1.2 CaCl2, 25 
NaHCO3, 1.6 KH2PO4, 0.4 K2HPO4, 5.5 glucose and 20 HEPES, 
pH 7.4 (GK-HEPES buffer). IEC-6 or Caco-2 cells were then 
incubated for 1h at 37ºC with tBOOH (100, 1000 or 3000 μM) in 
GK-HEPES buffer. The effect of antioxidants and inhibitors of 
intracellular signalling pathways was tested by incubating IEC-6 
cells in GK-HEPES buffer containing these compounds (or the 
respective solvents) for 20 min followed by incubation with 
tBOOH 3000 μM for 1h in the presence of these compounds (or 
the respective solvents).  
 
2.3. Evaluation of tBOOH-induced oxidative stress 
 
The magnitude of oxidative stress induced by tBOOH was 
indirectly evaluated, by measuring total (GSx), oxidized (GSSG) 
and reduced (GSH) glutathione levels and generation of lipid 
peroxidation products and protein carbonyl groups. 
 
2.3.1 Measurement of total (GSx), oxidized (GSSG) and 
reduced (GSH) glutathione levels  
 
IEC-6 cells were seeded on 24-well plates and submitted to 
treatment with tBOOH. Measurement of intracellular GSx levels  
was carried out according to a previously published method 
VIII - The effect of oxidative stress on the intestinal epithelial uptake of butyrate 
120 
 
(Capela et al.,  2007). Briefly, cultured cells were scraped and 
proteins precipitated with perchloric acid 5%, then centrifuged for 
10 min at 4ºC and the supernatant was neutralized with an 
equimolar solution of KHCO3. GSx content was measured by the 
rate of colorimetric change of 0.7 mM 5,5-dithiobis(nitrobenzoic 
acid) at 415 nm in the presence of 0.4 U of GSH redutase and 0.24 
mM NADPH, using a microplate reader. GSSG was also  
quantified, using 2-vinylpiridine to block free SH groups. GSH 
levels were calculated according to the following reaction: GSx = 
GSH + 2 GSSG. 
 
2.3.2. Measurement of lipid peroxidation products (TBARS 
assay) 
 
IEC-6 cells were seeded on 12-well plates and submitted to 
treatment with tBOOH. The extent of lipid peroxidation, which can 
be determined as the formation of malondialdehyde after the 
breakdown of polyunsaturated fatty acids, was measured by the 
thiobarbituric acid reactive substances (TBARS) assay (Fernandes 
et al., 1995). Briefly, 300 μl of cell suspension was precipitated 
with 200 μl of 50% trichloroacetic acid (TCA) and centrifuged for 
1 min at 6000 rpm. 300 μl of the supernatant were added to an 
equal volume of 1% thiobarbituric acid and the mixture was heated 
for 40 minutes at 95ºC, allowed to cool and the absorvance 
measured at 535 nm. 
 
2.3.3. Measurement of protein carbonyl groups 
 
IEC-6 cells were seeded on 12-well plates and submitted to 
treatment with tBOOH. Carbonyl (CO) groups (aldehydes and 
ketones) are produced on protein side chains when they are 
oxidized. Protein carbonyl content is the most used marker of 
protein oxidation (Dalle-Donne et al., 2003). The detection of 
protein carbonyl groups involves their reaction with 2,4-
dinitrophenylhydrazine (DNPH), which leads  to the formation of a 
stable 2,4-dinitrophenyl (DNP) hydrazone product, followed by the 
spectrophotometric quantification of the acid hydrazones (Levine 
et al., 1990). Briefly, carbonyl content was measured in the 
resultant pellet, that was treated with 0.5 ml of 2,4-
dinitrophenylhydrazine (10 mM in HCl 2 M) or 0.5 ml of HCl 2 M 
for the blank. Samples were incubated for 1h at room temperature, 
vortexing every 10 min. 0.5 ml of TCA 20% was added to each 
tube which was allowed to stand for 15 min at 4°C. The resultant 
pellet was washed 3 times with ethanol-ethyl acetate (1:1), 
centrifuged at 13000 rpm for 2 min at 4°C and dissolved in 1 ml 
guanidine 6 M overnight. The solution was then centrifuged at 
3000 rpm for 15 min. Absorbance was read at 340 nm and 
carbonyl content was calculated using the extinction coefficient of 
22 000 M−1 cm−1. 
 
2.4. Evaluation of tBOOH effect on cell viability 
 
2.4.1. Quantification of extracellular LDH activity 
 
IEC-6 cells were seeded on 24-well plates and submitted to 
treatment with tBOOH (100, 1000 and 3000 μM). Cellular leakage 
of the cytosolic enzyme lactate dehydrogenase (LDH) into the 
extracellular medium was measured spectrophotometrically by 
measuring the decrease in absorbance of NADH during the 
reduction of pyruvate to lactate, as described by Bergmeyer and 
Bernt (Bergmeyer, 1974). 
 
2.4.2. Sulforhodamine B (SRB) assay 
 
IEC-6 cells were seeded on 24-well plates and submitted to 
treatment with tBOOH (100, 1000 and 3000 μM). After treatment, 
62.5 µl of ice-cold 50% (w/v) TCA were added to the culture 
medium on each well to fix cells (1h at 4°C in the dark). The plates 
were then washed five times with tap water to remove TCA. Plates 
were air-dried and then stained for 15 min with 0.4% (w/v) SRB 
dissolved in 1% (v/v) acetic acid. SRB was removed and cultures 
were rinsed four times with 1% (v/v) acetic acid to remove residual 
dye. Plates were again air-dried and the bound dye was then 
solubilized with 375 µl of 10 mM Tris.NaOH solution (pH 10.5). 
The absorbance of each well was determined at 540 nm 
(Goncalves et al., 2011b). 
 
2.4.3. MTT (3-{4,5-dimethyl-2-thiazolyl}-2,5-diphenyl-2H-
tetrazolium bromide) assay 
 
IEC-6 cells were seeded on 24-well plates and submitted to 
treatment with tBOOH (1000 and 3000 μM). After treatment, 50 µl 
MTT solution (5 mg/ml) were added to each well. The cells were 
then further incubated for 3 h at 37 ºC. The formazan crystals 
derived from MTT cleavage were then measured as described by 
(Mosmann, 1983). 
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2.5. Determination of 14C-BT uptake 
 
Uptake experiments were performed with IEC-6 or Caco-2 
cells incubated in GK-MES buffer (GK buffer in which HEPES is 
substituted by an equimolar concentration of MES), pH 6.5 (except 
in pH-dependence experiments), after treatment with tBOOH. In 
the experiments of Na+ dependence, NaCl was substituted by an 
equimolar concentration of LiCl.  
Initially, the buffer was aspirated and the cells were washed 
with 0.3 ml buffer GK-MES at 37ºC; then, the cell monolayers 
were preincubated for 20 min in 0.3 ml GK-MES buffer at 37ºC. 
Uptake of 14C-BT was initiated by addition of 0.3 ml GK-MES 
buffer at 37ºC containing 14C-BT 10 µM (except in kinetic 
experiments). At the end of the incubation period (3 min, except in 
time-course experiments), incubation was stopped by placing the 
cells on ice and rinsing the cells with 0.3 ml ice-cold GK-MES 
buffer. The cells were then solubilized with 0.3 ml 0.1% (v/v) 
Triton X-100 (in 5 mM Tris-HCl, pH 7.4), and placed at 37ºC 
overnight. Radioactivity in the cells was measured by liquid 
scintillation counting.  
 
2.6. Determination of 14C-BT efflux 
 
Initially, the culture medium was aspirated, and the cells were 
washed twice with 0.3 ml of GK-MES buffer at 37°C. Then the 
cell monolayers were preincubated for 1h with 0.3 ml of GK-MES 
buffer at 37°C, and uptake was initiated by the addition of 0.3 ml 
of GK-MES buffer at 37°C containing 14C-BT 10 µM. Incubation 
was stopped after 30 min by removing the incubation buffer and 
rinsing the cells with 0.5 ml of ice-cold buffer. Then, efflux was  
measured by incubating the cells with 0.3 ml of GK-MES buffer at 
37°C for 20 min. At the end of this period, the medium was  
collected, and the cells were solubilized with 0.3 ml of 0.1% (v/v) 
Triton X-100 (in 5 mM Tris·HCl, pH 7.4) and placed at room 
temperature overnight. Radioactivity in both the efflux buffer and 
the cells was measured by liquid scintillation counting. 
Compounds to be tested were present during the efflux period 
only. 
 
2.7. Reverse transcription quantitative real-time-PCR (qRT-
PCR) 
 
Total RNA was extracted from IEC-6 cells using the Tripure 
isolation reagent, according to the manufacturer’s instructions 
(Roche Diagnostics, Germany). Before cDNA synthesis, total 
RNA was treated with DNase I (Invitrogen Corporation, CA, 
USA) according to manufacturer’s instructions, and 10 g of 
resulting DNA-free RNA were reverse transcribed using 
Superscript Reverse Transcriptase II and random hexamer primers 
(Invitrogen Corporation) in 40 l of final reaction volume, 
according to the manufacturer’s instructions. Resulting cDNA was 
treated with RNase H (Invitrogen Corporation) to degrade 
unreacted RNA. For the quantitative real-time PCR, 2 l of the 40 
l reverse transcription reaction mixture were used. For the 
calibration curve, IEC-6 standard cDNA was diluted in five 
different concentrations. 
Real-time PCR was carried out using a LightCycler (Roche, 
Nutley, NJ, USA). 20 l reactions were set up in microcapillary 
tubes using 0.5 M of each primer and 4 l of SYBR Green master 
mix (LightCycler FastStart DNA MasterPlus SYBR Green I, 
Roche). Cycling conditions were as follows: denaturation (95ºC 
for 5 min), amplification and quantification (95ºC for 10 s, 
annealing temperature (AT) for 15 s, and 72ºC for 10 s, with a 
single fluorescence measurement at the end of the 72ºC for 10 s 
segment) repeated 50 times, a melting curve program ((AT + 10) 
ºC for 15 s and 95ºC with a heating rate of 0.1ºC/s and continuous 
fluorescence measurement), and a cooling step to 40ºC (30 s). 
Annealing temperatures (AT) and sequence of primers are 
indicated in Table 1. Data were analyzed using LightCycler® 4.05 
analysis software (Roche, Mannheim, Germany). 
 
 
 
2.8. Protein determination 
 
The protein content of cell monolayers was determined as  
described by Bradford (Bradford, 1976) using serum albumin as  
standard. 
 
2.9. Calculation and statistics  
 
For the analysis of the time course of 14C-BT uptake, the 
parameters of Eq.1 were fitted to the experimental data by a non-
linear regression analysis, using a computer-assisted method 
(Muzyka A, 2005). 
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A(t) represents the accumulation of 14C-BT at time, k in and kout 
are the rate constants for inward and outward transport, 
respectively, and t is the incubation time. Amax corresponds to the 
accumulation (A(t)) at steady state (t→∞). k in is given in nmol per 
milligram protein per min and kout in min
-1. In order to obtain 
clearance values, k in was converted to µl per milligram protein per 
min.  
For the analysis of the saturation curve of 14C-BT uptake, the 
parameters of the Michaelis-Menten equation were fitted to the 
experimental data (Muzyka A, 2005). 
Arithmetic means are given with SEM, and geometric means  
are given with 95% confidence limits. Statistical analysis of the 
difference between various groups was evaluated by the ANOVA 
test, followed by the Student-Newman-Keuls test. Statistical 
analysis of the difference between two groups was evaluated with 
Student’s t test. Differences were considered to be significant when 
P<0.05. 
 
2.10. Materials  
 
14C-BT ([1-14C]-n-butyric acid, sodium salt; specific activity 
30-60 mCi/mmol) (Biotrend Chemikalien GmbH, Köln, 
Germany); DMSO (dimethylsulfoxide), (−)-cis-3,3′,4′,5,5′,7-
hexahydroxy-flavane-3-gallate ((−)-epigallocatechin-3-gallate), 
(E)-3-(4-Methylphenylsulfonyl)-2-propenenitrile (Bay 11-7082), 
′5,7-trihydroxyisoflavone (genistein), 2-(4-morpholinyl)-8-phenyl-
1(4H)-benzopyran-4-one hydrochloride (LY-294,002), 3,3′,4′,5,6-
pentahydroxyflavone (quercetin), 3,4′,5-trihydroxy-trans-stilbene 
(resveratrol), 4′,5,7-trihydroxyisoflavone 7-glucoside (genistin), 
5,5-dithiobis(nitrobenzoic) acid, 2,4-dinitrophenylhydrazine 
(DNP), acetic acid sodium salt,  calmidazolium, chelerythrine 
chloride, colchicine, H-89 dihydrochloride hydrate, KN-62, 
decane, ethanol, GSH redutase, N-2-hydroxyethylpiperazine-N′-2-
ethanesulfonic acid (HEPES), (2-[N-morpholino] ethanesulfonic 
acid hydrate) (MES), M inimum Essential Medium, monensin 
sodium salt, nicotinamide adenine dinucleotide (NADH), β-
nicotinamide adenine dinucleotide phosphate (NADPH), PD 
98058,  penicillin/streptomycin/amphotericin B solution, pyruvic 
acid sodium salt, rapamycin, SB 203580, serum albumin, SP 
600125, sodium pyruvate,  sulforhodamine, tert-
butylhydroperoxide (tBOOH), thiobarbituric acid, trichloroacetic 
acid sodium salt, Tris-HCl, Tris.NaOH, trypsin–EDTA solution, 2-
vinylpiridine (Sigma, St. Louis, MO, USA); perchloric acid, triton 
X-100 (Merck, Darmstadt, Germany). 
Compounds to be tested were dissolved in H2O, decane, 
NaHCO3 (100 mM) dimethylsulfoxide or ethanol. The final 
concentration of these solvents in the buffer was 1%. Controls for 
these compounds were run in the presence of the respective 
solvent. 
 
3. Results 
 
3.1. Evaluation of tBOOH-induced oxidative stress in IEC-6 
cells  
 
IEC-6 cells were exposed to increasing concentrations of 
tBOOH, as described under Methods. Proposed mechanisms of 
tBOOH-induced toxicity include production of tert-butoxyl, 
peroxyl, alkoxyl and methyl radicals that catalyze lipid 
peroxidation, production of DNA stand breaks and alteration in 
intracellular calcium homeostasis following glutathione and 
protein thiol depletion (Aherne and O'Brien, 2000; Chamulitrat, 
1998). 
In order to assess the effect of tBOOH on IEC-6 cell oxidative 
stress levels, the cellular levels of total (GSx), oxidized (GSSG) 
and reduced (GSH) glutathione and GSH/GSSG ratio were 
determined. Treatment of IEC-6 cells with tBOOH 1000 and 3000 
μM for 1h induced a significant decrease in both GSx and GSH 
cellular levels, although GSSG levels were not significantly 
affected; consequently, a marked decrease in the GSH/GSSG ratio 
was observed (Fig. 1).  
To further evaluate the effect of tBOOH upon oxidative stress 
levels, we then measured the extent of lipid peroxidation, by using 
the TBARS assay (lipid peroxidation results in the formation of 
reactive aldehydes, including malondialdehyde), and the extent of 
protein carbonylation, by measuring protein carbonyl groups 
(produced on protein side chains when they are oxidized). tBOOH 
3000 μM significant increased the cellular concentration of 
malondialdehyde (MDA), indicating oxidative damage to cell 
lipids (Fig. 2A), and tBOOH 1000 and 3000 μM significant 
increased the cellular concentration of carbonyl groups, indicating 
oxidative damage to proteins (Fig. 2B). 
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Figure 1. Effect o f 1h-exposure to increasing concentrations of tBOOH (1000 
and 3000 µM) on IEC-6 total glutathione (GSx) levels (A), o xidized 
glutathione (GSSG) levels (B), reduced glutathione (GSH) levels (C) and 
GSH/GSSG ratio (D). Results are expressed as n mol/mg  protein (A, B and C) . 
Shown are arithmetic means±SEM (n=17-20). Statistical analysis was 
evaluated by the ANOVA test, followed by the Student -Newman-Keuls test. 
*Significantly different fro m control (P<0.05). 
 
Figure 2. E ffect of 1h-exposure to increasing concentrations of tBOOH (1000 
and 3000 µM) on  IEC-6 lipid peroxidation (A) and protein carbonyl (B) levels. 
(A) Lipid peroxidation was determined by quantification of MDA, as  described 
in Methods. Results are shown as nmol MDA /mg protein (n=18-20). (B) 
Protein carbonil groups were determined as described in Methods. Results are 
shown as nmol/mg protein (n=14). Shown are arithmetic means±SEM. 
Statistical analysis was evaluated by the ANOVA test, followed by the Student -
Newman-Keuls test. *Significantly diffe rent from control (P<0.05). 
 
 
3.2. Effect of tBOOH on IEC-6 cell viability 
 
Next, we evaluated the effect of tBOOH upon IEC-6 cellular 
viability. Exposure of IEC-6 cells to increasing concentrations of 
tBOOH (100, 1000 and 3000 µM) caused no increase in LDH 
leakage, indicating that these concentrations did not affect cell 
membrane integrity (Fig. 3A). Similarly , treatment with tBOOH 
(100, 1000 and 3000 µM) was devoid of effect upon IEC-6 whole-
cell protein (SRB assay) (Fig. 3B). Finally, tBOOH (1000 and 
3000 µM) did not affect MTT cleavage (Fig. 3C), indicating that 
these concentrations did not affect the mitochondrial metabolic 
capacity of IEC-6 cells. Altogether, these results indicate that 
treatment of IEC-6 cells for 1h with tBOOH 3000 μM induced a 
significant increase in ROS formation, as indicated by an 
enhancement in lipid peroxidation, protein carbonylation and by a 
decrease in GSx and GSH levels and in GSH/GSSG ratio, while 
having no impact on cell viability. In other studies, tBOOH was 
also used as oxidative stress inducer at similar concentrations 
(Couto MR, 2012; Deiana et al., 2010). So, tBOOH 3000 µM was 
used in subsequent experiments aimed at determining the effect of 
oxidative stress upon 14C-BT uptake by IEC-6 cells. 
 
Figure 3. E ffect o f 1h-exposure to increasing concentrations of tBOOH (100, 
1000, 3000 µM) on IEC-6 cell viability. (A) Quantification of extracellular 
LDH activity was done as described in Methods. Results are shown as 
extracellular LDH activity (% of total) (n=11-12). (B ) Whole cellular protein 
was quantified with the SRB assay as described in Methods. Results are shown 
% o f control (n=10-12). (C) The MTT assay was done as described in Methods. 
Results are shown as % of control (n=10). Shown are arithmetic means±SEM. 
Statistical analysis was evaluated by the ANOVA test, followed by the Student -
Newman-Keuls test. 
 
 
3.3. Effect of tBOOH upon 14C-BT uptake 
 
3.3.1. Effect upon the time-course of 14C-BT uptake in IEC-6 
cells  
 
In a first series of experiments, we determined the time-course 
of 14C-BT (10 µM) accumulation in IEC-6 cells. For this, cells  
were incubated at 37ºC with 14C-BT for various periods of time, in 
the absence or presence of a previous treatment with 3000 μM 
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tBOOH for 1h. As shown in Fig. 4A, treatment with tBOOH 
originated a reduced accumulation of 14C-BT over time. Analysis 
of the time-course of 14C-BT accumulation showed a marked 
decrease in the Amax in the presence of tBOOH (2.85±0.30 and 
0.36±0.03 nmol/mg prot in control and tBOOH-treated cells, 
respectively). 
 
Figure 4. Ti me-course (A) and kinetic parameters (B, C) of 14C-BT uptake by 
IEC-6 cells, a fter treat ment for 1h with tBOOH 3000 µM (tBOOH) or the 
respective solvent (Control). (A) Cells were  incubated at 37ºC with 10 µM 14C-
BT for  different periods of time (n=5-7). (B ) Initial rates of 14C-BT uptake were 
determined in cells incubated at 37°C with 0.01–3 mM o f 14C-BT for 3  min 
(n=6). (C) Initial rates of 14C-BT uptake were determined in cells incubated at 
4°C with 0.01–3 mM of 14 C-BT for  3  min (n=6-8). Shown are  arithmetic 
means±SEM. Statistical analysis was evaluated by the ANOVA test, followed 
by the Student-Newman-Keuls test. 
 
  
3.3.2. Effect upon the kinetics of 14C-BT uptake in IEC-6 cells 
 
The time-course results (section 3.3.1.) and previous results 
from our group (Goncalves et al., 2011a) show that the apical 
uptake of 14C-BT in IEC-6 cells is linear with time for up to 3 min 
of incubation. So, the kinetics of 14C-BT uptake by IEC-6 cells was 
next determined, by measuring initial rates of 14C-BT uptake at 
increasing substrate concentrations (10-3000 μM) at 37ºC for 3 
min. We verified that tBOOH 3000 µM was devoid of significant 
effect upon the kinetics of 14C-BT uptake (Vmax=78.5±22.5 and 
94.4±40.4 nmol mg prot−1 3 min−1; Km=5.14±2.14 and 5.38±3.29 
mM, in control and tBOOH-treated cells, respectively). However, 
analysis of the saturation curve reveals that tBOOH decreased 
uptake of low concentrations and increased uptake of high 
concentrations of 14C-BT (Fig. 4B). 
At 37ºC both carrier and non-carrier mediated mechanisms of 
transport are functional. To distinguish between the two routes of 
transport, we also performed saturation curves at 4ºC. In this 
condition, only the non-carrier mediated transport is present. As 
shown in Fig. 4C, uptake of 14C-BT at 4°C was linear with 
increasing concentrations of 14C-BT, and treatment with tBOOH 
increased the slope of 14C-BT uptake, compared to control 
(0.01884±0.00054 and 0.01505±0.00027 for control and tBOOH-
treated cells, respectively). So, tBOOH increased passive 
diffusional uptake of 14C-BT. However, it should be noted that this 
was found only for high concentrations of BT (2 mM and above); 
for the concentration of 14C-BT used in most of the experiments of 
this study (10 µM), passive diffusional transport has a minor 
importance. 
 
3.3.3. Effect upon MCT1- and SMCT1-mediated 14C-BT uptake 
 
Uptake of 14C-BT by IEC-6 cells involves both MCT1- and 
SMCT1- mediated transport (Goncalves et al., 2011a). To 
distinguish between the effect of tBOOH upon MCT1-mediated 
(extracellular Na+-independent) and SMCT1-mediated 
(extracellular Na+-dependent) uptake, we compared the inhibitory 
effect of tBOOH on 14C-BT accumulation in the presence (total 
uptake) and absence of NaCl (Na+-independent uptake), at 
different pHs (Fig. 5).  
In agreement with a previous publication from our group 
(Goncalves et al., 2011a), 14C-BT uptake by IEC-6 cells involves  
both a Na+-dependent and a Na+-independent component (Figs. 5A 
and 5B). In both control and tBOOH-treated cells, total and Na+-
independent 14C-BT uptake was strongly pH-dependent, being 
significantly increased with a decrease in pH (Figs. 5A and 5B). 
Interestingly enough, tBOOH strongly inhibited total 14C-BT 
uptake (MCT1 and SMCT1-mediated uptake), but did not inhibit 
(and even increased, at pH 7.5) Na+-independent (MCT1-
mediated) uptake of 14C-BT. We can thus conclude that tBOOH 
inhibits SMCT1-mediated uptake of 14C-BT in IEC-6 cells, but 
does not affect MCT1-mediated uptake. In order to confirm this 
conclusion, we decided to investigate the effect of tBOOH in 
Caco-2 cells, in which BT uptake is mainly MCT1-mediated 
(Goncalves et al., 2009). Our group had previously shown that the 
apical uptake of 14C-BT in Caco-2 cells was linear with time for up 
to 3 min of incubation (Goncalves et al., 2009) and that 3000 µM 
tBOOH for 1h induced oxidative stress (Couto MR, 2012). As 
shown in Fig. 5C, tBOOH was devoid of effect upon 14C-BT 
uptake in Caco-2 cells, supporting the conclusion that oxidative 
stress does not affect MCT1-mediated transport. 
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Figure 5. (A) E ffect o f tBOOH on 14C-BT uptake by IEC-6 cells in the presence 
of extracellular Na+ (total uptake). (B ) Effect o f tBOOH on 14C-BT uptake by 
IEC-6 cells in the absence of extracellular Na+ (Na+-independent uptake). (C) 
Effect o f tBOOH on 14C-BT uptake by Caco-2 cells. (D) Effect of tBOOH on 
14C-BT efflux fro m IEC-6  cells.  (A)  Cells were incubated at 37ºC for  3 min 
with 14C-BT (10  µM) in GK-MES (pH 5.5 and 6.5)  or  GK-HEPES (pH 7.5) 
buffer, in the absence (control) or presence of a previous exposure to tBOOH 
3000 µM (tBOOH) for 1h (n=9-12). (B )  Cells were incubated at 37ºC for 3 min 
with 14C-BT (10  µM) in GK-MES (pH 5.5 and 6.5)  or  GK-HEPES (pH 7.5) 
buffer where NaCl was isotonically replaced by LiCl, in the absence (control) or 
presence of a previous exposure to tBOOH 3000 µM (tBOOH) for  1h (n=6-12). 
(C) Initial rates of 14C-BT uptake were determined in Caco-2 cells incubated at 
37°C with 14C-BT (10 µM) for 3  min, a fter treat ment  for 1h with tBOOH 3000 
µM (tBOOH) or the respective solvent (Control) (n=14-15). (D) Cells were 
incubated in GK-MES (pH 6.5) at 37ºC for 30 min with 14C-BT (10 µM), and 
then efflux o f 14C-BT fro m the cells was measured for  20 min, in the absence or 
presence of tBOOH (3000 µM) or  Ko143 1 µM (Ko143), as explained in the 
Methods (n=8-12). Results are shown as nmol/mg protein (arithmetic 
means±SEM). Statistical analysis was evaluated by the ANOVA test, followed 
by the Student-Newman-Keuls test. *Significantly different from the  respective 
control; #Significantly different fro m pH 5.5 (P<0.05). 
 
 
3.3.4. Effect of tBOOH upon 14C-BT efflux 
 
The intracellular accumulation of 14C-BT depends not only on 
uptake mechanisms, but is also dependent on efflux mechanisms, 
which are able to remove 14C-BT from the cells. So, we decided to 
investigate also the effect of tBOOH upon 14C-BT efflux from 
IEC-6 cells.  
As shown in Fig. 5D, efflux of 14C-BT from IEC-6 cells was 
strongly increased by tBOOH. BCRP was recently found to be 
involved in the efflux of 14C-BT in IEC-6 cells (Goncalves et al.,  
2011b). In order to investigate if tBOOH affects BCRP-mediated 
14C-BT efflux, we tested the influence of a BCRP inhibitor (Ko143 
1µM) (Allen et al., 2002). In agreement with the fact that 14C-BT is 
effluxed out of the cells through BCRP, Ko143 decreased efflux of 
14C-BT in control cells. However, in the presence of tBOOH, 
efflux of 14C-BT was not affected by Ko143, indicating that BCRP 
is not involved (Fig. 5D).  
 
3.4. Effect of tBOOH upon MCT1 and SMCT1 mRNA levels in 
IEC-6 cells 
 
A comparison between the mRNA steady-state levels of MCT1 
and SMCT1 in control and tBOOH-treated IEC-6 cells, evaluated 
by qRT-PCR, shows that MCT1 and SMCT1 mRNA levels were 
similar in control and tBOOH-treated cells (Fig. 6).  
 
Figure 6. Quantification of mRNA levels of rat H +-coupled monocarboxylate 
transporter 1 (MCT1)  and rat  Na+-coupled monocarboxylate cotransporter 
(SMCT1), by qRT-PCR, in IEC-6 cells a fter treat ment for 1h with tBOOH 3000 
µM (tBOOH) or  its solvent (Control; n=5). Results are shown as the expression 
of MCT1 or SMCT1 relative to GAPDH (arithmetic means±SEM). Statistical 
analysis was evaluated with Student’s t  test. * Significantly different fro m 
control (P<0.05). 
 
3.5. Effect of modulators of intracellular signaling pathways  
on tBOOH-induced inhibition of 14C-BT uptake in IEC-6 cells 
 
Next, we investigated the signaling mechanisms that are 
involved in the inhibition of 14C-BT uptake caused by tBOOH in 
IEC-6 cells. The signaling pathways investigated were chosen 
based on the fact that they are known to be activated by ROS: 
protein kinase C, mitogen-activated protein kinases (MAPKs), 
phosphatidylinositol-3-kinase/Akt/mTOR pathway, nuclear factor-
kappaB (NF-kB) signaling, and protein tyrosine kinases (Benhar et 
al., 2002; Liu et al., 2006; Poli et al., 2004; Wu, 2006). 
First, because oxidative stress led to elevations of cytosolic 
Ca2+ concentration (Stone et al., 1994) and a synergistic action of 
Ca2+ is required for activation of classical Ca2+-mediated protein 
kinase C (Nishizuka, 1986), we analyzed the effect of the 
Ca2+/calmodulin inhibitor calmidazolium and of the 
Ca2+/calmodulin-dependent protein kinase II inhibitor KN-62 (Said 
et al., 1999) upon tBOOH-induced inhibition of 14C-BT uptake. 
Although uptake of 14C-BT was significantly reduced in the 
presence of these agents, suggesting that BT uptake is dependent 
on intracellular Ca2+/calmodulin and Ca2+/calmodulin-dependent 
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protein kinase II, the effect of tBOOH upon 14C-BT uptake was not 
changed by any of them (Fig. 7A). 
Next, we studied the effect of specific inhibitors of protein 
kinase C (chelerythrine) (Herbert et al., 1990) and protein kinase A 
(H-89) (Chijiwa et al., 1990). H89 was devoid of effect, but 
chelerythrine markedly reduced 14C-BT uptake, which is in 
agreement with previous studies showing that 14C-BT uptake is 
stimulated by protein kinase C (Alrefai et al., 2004; Gonçalves P., 
2012). However, the effect of tBOOH was also not changed in the 
presence of these agents (Fig. 7A).  
The involvement of mitogen-activated protein (MAP) kinases 
was studied by testing the effect of specific inhibitors of mitogen-
activated protein kinase (MAPK) extracellular signal regulated 
kinase 1/2 (ERK1/2) (PD 98059) (Dudley et al., 1995), p38 MAPK 
(SB 203580) (Cuenda et al.,  1995) and c-Jun-NH2-terminal kinases  
(JNK) (SP 600125) (Bennett et al., 2001). PD 98059, SB 203580 
and SP 600125 were devoid of effect upon 14C-BT uptake, and SB 
203580 and SP 600125 also did not change the inhibitory effect of 
tBOOH upon 14C-BT uptake. However, PD 98059 slightly 
decreased it, suggesting that inhibition of 14C-BT uptake by 
tBOOH depends on MAPK ERK1/2 activation (Fig. 7A).  
Next, the involvement of the phosphatidylinositol-3-
kinase/Akt/mTOR pathway was studied by testing the effect of 
specific inhibitors of phosphatidylinositol-3-kinase (LY 294002) 
(Vlahos et al.,  1994) and mTOR (rapamycin) (Brown et al., 1994). 
Rapamycin was devoid of effect upon 14C-BT uptake, but LY 
294002 reduced it by 10%, thus appearing that BT uptake is 
dependent on activation of this pathway. However, the effect of 
tBOOH was not changed in the presence of these agents (Fig. 7B).  
The involvement of nuclear factor-kappa B (NFκB) signal 
transduction pathway was studied by testing the effect  of BAY 11-
7082, a specific inhibitor of IkBa phosphorylation and degradation 
(Pierce et al., 1997). BAY 11-7082 was devoid of effect upon 14C-
BT uptake and upon the inhibitory effect of tBOOH on this 
parameter (Fig. 7B).  
Finally, we also tested for the involvement of protein tyrosine 
kinases (PTKs) in tBOOH-mediated inhibition of 14C-BT uptake 
by using genistein, a known PTK inhibitor (Akiyama et al., 1987). 
As shown in Fig. 7B, genistein, but not its negative control 
genistin (which does not exerts inhibition of PTK) reduced 14C-BT 
uptake and decreased the inhibitory effect of tBOOH upon 14C-BT 
uptake, suggesting that both BT uptake and inhibition of 14C-BT 
uptake caused by tBOOH are dependent on PTK activation. 
Cytoskeletal elements, such as microtubules, actin filaments, 
and their associated molecular motors, are intimately involved in 
mechanical signaling (Janmey, 1998). Because oxidative stress 
induced internalization of the bile salt export pump (Perez et al., 
2006) we also tested the involvement of this mechanism in the 
inhibitory effect of tBOOH upon 14C-BT uptake, by testing the 
effect of a microtubule disruptor (colchicine) (Malawist.Se and 
Bensch, 1967). The observation that colchicine was devoid of 
effect upon 14C-BT uptake and did not change the effect of tBOOH 
upon it, demonstrates that oxidative stress does not affect 14C-BT 
uptake by substantially altering the cellular distribution of BT 
transporters (Fig. 7B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. In fluence of inhibitors of intracellular signalling pathways upon the 
inhibitory effect o f tBOOH on 14C-BT uptake by IEC-6 cells. (A) Cells were 
exposed to tBOOH 3000 µM (tBOOH), cal midazolium 25 µM (CALM), 
tBOOH+calmidazolium 25 µM (tBOOH+CALM), KN-62 10 µM (KN), 
tBOOH+KN-62 10 µM (tBOOH+KN), chelerythrine 10 µM (CHEL), 
tBOOH+chelerythrine 10 µM (tBOOH+CHEL), H-89 10 µM (H89), 
tBOOH+H-89 10 µM (tBOOH+H89), PD 98058 25 µM (PD), tBOOH+PD 
98058 25 µM (tBOOH+PD), SB 203580 25 µM (SB), tBOOH+SB 203580 2.5 
µM (tBOOH+SB), SP 600125 25 µM (SP), tBOOH+SP 600125 25 µM 
(tBOOH+SP), or the respective solvents, as described in Methods (n=7-22). (B ) 
Cells were exposed to tBOOH 3000 µM (tBOOH), LY 294002 10 µM (LY), 
tBOOH+LY 294002 10 µM (tBOOH+LY), rapamycin 500 nM (RAPA), 
tBOOH+rapamycin 500 nM (tBOOH+RAPA), BAY 11-7082 5 µM (BAY), 
tBOOH+BAY 11-7082 5 µM (tBOOH+BAY), genistein 50 µM (GEN), 
tBOOH+genistein 50 µM (tBOOH+GEN), genistin 50 µM (GENI), 
tBOOH+genistin 50 µM (tBOOH+GENI), colchicine 10 µM (COL), 
tBOOH+colchicine 10 µM (tBOOH+COL) or the respective solvents, as 
described in Methods (n=6-12). Shown are arithmetic means±SEM. Statistical 
analysis was evaluated by the ANOVA test, followed by the Student -Newman-
Keuls test.  * significantly different fro m the respective control (P<0.05) # 
significantly different fro m tBOOH (P<0.05). 
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3.6. Effect of inhibitors of ROS generating enzymes on tBOOH-
induced inhibition of 14C-BT uptake in IEC-6 cells  
 
ROS are produced via a variety of cellular oxidative metabolic 
processes, including NADPH oxidase, xanthine oxidase, 
arachidonic acid metabolism by cyclooxygenases and 
lipoxygenases, and the mitochondrial respiratory chain (Kim et al.,  
2008). We demonstrated that the inhibition of 14C-BT uptake in 
IEC-6 cells by tBOOH was dependent on MAPK ERK1/2 
activation. Previous studies indicate that ERK1/2 activation leads  
to an increase in NADPH oxidase (Cevik et al., 2008; Choudhary 
et al., 2011; Dewas et al., 2000; Seru et al., 2004), xanthine 
oxidase (Abdulnour et al., 2006) and cytosolic phospholipase A2 
(cPLA2) (Askarova et al., 2011; Borowitz and Montgomery, 1989) 
activities and thus in ROS production. So, we investigated the 
involvement of ROS-generating enzymes in the inhibition of 14C-
BT uptake in response to tBOOH. 
The NADPH oxidase inhibitor apocynin (Stolk et al., 1994) 
and the well known xanthine oxidase inhibitor allopurinol 
(Delgado et al.,  1966) were devoid of effect upon 14C-BT uptake 
but slightly decreased the inhibitory effect of tBOOH on 14C-BT 
uptake (Fig. 8A), suggesting the involvement of NADPH oxidase 
and xanthine oxidase in the inhibition of 14C-BT uptake by 
tBOOH. 
Finally, the involvement of phospholipase A2 may be excluded 
because its inhibitor quinacrine (Winocour et al., 1981) had no 
effect upon 14C-BT uptake and did not change the effect of tBOOH 
upon 14C-BT uptake (Fig. 8A). 
 
 
3.7. Effect of antioxidants on tBOOH-induced inhibition of 
14C-BT uptake and increase in lipid peroxidation in IEC-6 cells  
 
Reducing oxidative stress levels with antioxidant therapy is 
one of the strategies of chemoprevention (Roessner et al., 2008). 
So, in the last part of this work, we investigated the effect of some 
antioxidants in the inhibitory effect of tBOOH upon 14C-BT 
uptake. We tested the ROS scavenger N-acetyl-cysteine, vitamin 
C, and the polyphenols epigallocatechin-3-gallate, quercetin and 
resveratrol (Wojcik et al., 2010).   
As shown in Fig. 8B, apart from epigallocatechin-3-gallate, all 
tested antioxidants significantly reduced 14C-BT uptake. The 
inhibitory effect of quercetin and resveratrol was already described 
by our group (Goncalves et al.,  2011a). Interestingly enough, the 
inhibitory effect of tBOOH upon 14C-BT uptake was strongly 
reduced by quercetin and resveratrol, although N-acetyl-cysteine, 
vitamin C and epigallocatechin-3-gallate had no effect. The 
inhibitory effect of quercetin upon tBOOH-induced changes in 
14C-BT uptake correlated well with its inhibitory effect upon 
tBOOH-induced oxidative damage, as evaluated by quantification 
of lipid peroxidation. Indeed, although quercetin alone was devoid 
of effect in this parameter (97.7±21.9% of control, n=12), it 
completely abolished the increase in lipid peroxidation caused by 
tBOOH (from 431.5±42.6% to 105.4±28.4 of control in the 
absence and presence of quercetin, respectively; n=12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Influence of  inhibitors of ROS generating enzymes (A) and 
antioxidants (B ) upon the inhibitory effect o f tBOOH on 14C-BT uptake by IEC-
6 cells. (A) Cells were exposed to tBOOH 3000 µM (tBOOH), apocynin 1 mM 
(APO), tBOOH+apocynin 1 mM (tBOOH+APO), allopurinol 1 mM (ALLO), 
tBOOH+allopurinol 1 mM (tBOOH+ALLO), quinacrine 5 μM (QUIN), 
tBOOH+quinacrine 5 μM (tBOOH+QUIN), or the respective solvents, as 
described in Methods (n=12). (B ) Cells were exposed to tBOOH 3000 µM 
(tBOOH), N-acetyl-cysteine 1 mM (NAC), tBOOH+N-acetyl-cysteine 1 mM 
(tBOOH+NAC), vitamin C 100 µM (VIT C), tBOOH+vitamin C 100 µM 
(tBOOH+VIT C), epigallocatechin-3-gallate 50 μM (EGCG), 
tBOOH+epigallocatechin-3-gallate 50 μM (tBOOH+EGCG), resveratrol 50 μM 
(RESV), tBOOH+resveratrol 50 μM (tBOOH+RESV), quercetin 50 μM 
(QUER), tBOOH+quercetin 50 μM (tBOOH+QUER), or the respective 
solvents, as described in Methods (n=9-10). Statistical analysis was evaluated 
by the ANOVA test, followed by the Student-Newman-Keuls test.  Shown are 
arithmetic means±SEM. * significantly different fro m the respective control 
(P<0.05) #significantly different fro m tBOOH (P<0.05). 
 
4. Discussion 
Based in previous studies (see Introduction) we chose tBOOH 
as a model to investigate intestinal oxidative stress. To validate this 
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model in IEC-6 cells, we exposed the cells to increasing 
concentration of tBOOH for 1h and then quantified some 
biomarkers of oxidative stress, and investigated the effect of 
tBOOH upon cell viability. In IEC-6 cells treated with 1000 and 
3000 μM tBOOH, a significant decrease in both GSx and GSH 
levels was observed. GSH is the major endogenous thiol 
antioxidant, having an extensive role in the preservation of cellular 
redox balance as well as in the detoxification of exogenous and 
endogenous compounds (Dickinson and Forman, 2002). 
Accordingly, the observed decrease in GSH level is a good 
indicator of oxidative stress both in vitro and in vivo (Rossi et al., 
2006). Oxidative stress induces cellular injury through the 
production of free radicals of high reactivity, leading to membrane 
lipid peroxidation (Poli et al., 1987) and oxidation of critical thiol 
groups, causing formation of homo- and heteroproteins bound by 
disulfide bridges (Di Monte et al., 1984), thus altering protein 
structure and function (Ottaviano et al., 2008). So, we also 
measured the extent of lipid peroxidation (TBARS assay) and 
protein carbonylation in response to tBOOH. We found a 
significant increase in lipid peroxidation in cells treated with 3000 
μM tBOOH, and a significant increase in protein carbonylation in 
cells treated with tBOOH 1000 and 3000 μM. 
As a whole, our results indicate that tBOOH seems to induce 
oxidative stress in IEC-6 cells, particularly at 3000 μM. This 
concentration of tBOOH had no impact on IEC-6 cell viability. 
Based on these results, we could conclude that IEC-6 cells  
submitted to treatment with 3000 μM tBOOH for 1h constitute a 
good cellular model to study the effects of oxidative stress upon 
the intestinal absorption of BT. We thus chose tBOOH 3000 μM 
for subsequent experiments. 
The effect of tBOOH upon uptake of a low concentration of 
14C-BT (10 µM) by IEC-6 cells can be summarized as follows: (a) 
tBOOH caused a reduction in the intracellular accumulation of 
14C-BT over time; (b) tBOOH strongly reduced total 14C-BT 
uptake but did not affect (or even increased) Na+-independent 
uptake of 14C-BT, and (c) tBOOH did not affect the kinetics of 
14C-BT uptake at 37°C (although it decreased uptake of low 
concentrations and increased uptake of high concentrations of 14C-
BT) and increased uptake of 14C-BT at 4°C. Moreover, tBOOH 
increased the efflux of 14C-BT not mediated by breast cancer 
resistance protein. From these results, we conclude that tBOOH 
strongly inhibits SMCT1-mediated BT uptake, while having no 
effect on MCT1-mediated BT transport, and increases both uptake 
and efflux of BT through passive diffusion. 
The conclusion that tBOOH inhibits SMCT1- but not MCT1-
mediated BT uptake was based in the observation that tBOOH 
reduced Na+-dependent but not Na+-independent uptake of 14C-BT 
by IEC-6 cells, together with the fact that tBOOH was devoid of 
effect upon 14C-BT uptake in Caco-2 cells, which is mainly 
MCT1-mediated (Goncalves et al., 2009). Moreover, inhibition of 
uptake of only low concentrations of 14C-BT also supports the 
conclusion that tBOOH inhibits SMCT1, because MCT1 has a low 
affinity/high transport capacity (Km is about 2.6 mM BT) 
(Goncalves et al., 2009), and SMCT1 has a high affinity/low 
transport capacity (Km is about 50 µM BT) (Thangaraju et al.,  
2008). SMCT1 depends on an intact Na+ gradient which is 
maintained by the Na+/K+-ATPase (Coady et al., 2004). 
Interestingly, this may constitute a link between tBOOH and 
reduced SMCT1 activity, as ROS were found to reduce Na+/K+-
ATPase membrane expression and activity (Thomas and Reed, 
1990; Ogimoto et al., 2000).  
We conclude that tBOOH increases BT uptake through passive 
diffusion because it increased uptake of 14C-BT at 4°C, at which 
only noncarrier-medicated processes are operating, and also on the 
observation that uptake of high concentrations of 14C-BT is 
increased by tBOOH at 37°C, a temperature at which both carrier 
and noncarrier-mediated mechanisms operate. As expected for a 
passive mechanism, this increase in diffusion of BT through the 
lipid bilayer in response to tBOOH is most evident for high 
concentrations of BT. Finally, the conclusion that tBOOH 
increases BT efflux not mediated by BCRP is based on the 
observation that tBOOH induced a Ko143-independent increase in 
14C-BT efflux. The stimulatory effect of tBOOH upon BT passive 
diffusion may well be related to the observed increase in lipid 
peroxidation caused by this agent. Moreover, it appears to be a 
specific effect, because tBOOH did not increase the efflux of 
another compound (5-methyltetrahydrofolate; results not shown).  
Oxidative stress, and ROS in particular, can modulate 
transporter function by a number of mechanisms, including: 1) 
transcriptional regulation of gene expression; 2) changes in the 
gain in other signaling pathways that may in turn lead to changes  
in transporter activity or transporter gene expression; and 3) post -
translational modifications of transporter structure (formation of 
intra- or inter-protein cross linked derivatives, peptide cleavage, 
nitrosylation, nitration, and oxidation of key amino acid residues  
with production of hydroxyl or carbonyl derivatives) (Matalon et 
al., 2003). From our qRT-PCR results, we conclude that tBOOH 
caused no changes in gene expression of MCT1 and SMCT1, the 
two main transporters involved in BT uptake by IEC-6 cells, 
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suggesting that oxidative stress affected transporter function at a 
post-transcriptional level. Moreover, the lack of effect of 
colchicine upon the inhibitory effect of tBOOH on 14C-BT uptake 
points to the conclusion that tBOOH also did not affect the amount 
of protein transporters inserted in the cell membrane. On the 
contrary, our results suggest that tBOOH may be acting directly in 
protein structure, because tBOOH increased protein carbonylation. 
Protein carbonyl groups (aldehydes and ketones) are generated by 
direct oxidation of amino acid residues, particularly lysine, 
arginine, threonine, and proline (Dalle-Donne et al., 2003). Such 
modifications in proteins result in important changes in protein 
structure and possibly function. Of note, recently Simão et al.  
(Simao et al., 2011) demonstrated that ROS stimulate Cl-/HCO3
- 
exchanger activity through oxidation of thiol groups. 
Because oxidative stress is known to activate several 
intracellular signaling pathways (Benhar et al., 2002; Liu et al.,  
2006; Poli et al., 2004; Wu, 2006), we decided to clarify the role of 
intracellular regulatory pathways in the effect of 14C-BT uptake by 
tBOOH. These experiments showed that the inhibitory effect of 
tBOOH upon 14C-BT uptake was partially reversed by genistein 
(but not by genistin) and by PD 98059, suggesting that inhibition 
of 14C-BT uptake by tBOOH was dependent on PTK and MAPK 
ERK1/2 activation. 
Inhibition of oxidative stress damage constitutes the first line 
of defense against carcinogenic insults and can be considered the 
most effective way for preventing cancer. Two different 
pharmacological approaches can be employed to counteract 
oxidative stress: selective inhibitors of various enzymatic sources 
of ROS, and antioxidant supplements (e.g., vitamins C, 
polyphenols).  
ROS are produced through a variety of cellular oxidative 
metabolic processes, including NADPH oxidase, xanthine oxidase 
and arachidonic acid metabolism by cyclooxygenases and 
lipoxygenases (Kim et al., 2008). Because apocynin and 
allopurinol partially reversed the effect of tBOOH upon 14C-BT 
uptake, inhibition of 14C-BT uptake by tBOOH is dependent on 
generation of ROS by NADPH oxidase and xanthine oxidase; 
namely O2
•- by NADPH oxidase, and O2
•- and H2O2 by xanthine 
oxidase (Sato et al.,  2011). Studies have demonstrated that 
pharmacological inhibition of NADPH oxidase may be more 
effective in modulating ROS production than scavenging of ROS 
by antioxidant supplements (Jaquet et al., 2009). So, use of 
NADPH and xanthine oxidase selective inhibitors can be useful to 
counteract the effect of oxidative stress upon 14C-BT uptake.  
Finally, we also investigated the ability of some antioxidants 
(N-acetyl-cysteine, vitamin C, epigallocatechin-3-gallate (EGCG), 
quercetin and resveratrol) to reduce/prevent the inhibition of 14C-
BT uptake caused by tBOOH. We verified that quercetin and 
resveratrol significantly decreased the inhibitory effect of tBOOH 
upon 14C-BT uptake. Dietary polyphenols are considered to be 
antioxidants, due to their ability to directly scavenge ROS and to 
modulate the expression of antioxidant enzymes (Antosiewicz et 
al., 2008). Of these, quercetin and resveratrol were shown to have 
strong antioxidant activities (Kaindl et al., 2008; Pulido et al.,  
2000; Wolfe and Liu, 2007).  Interestingly, the inhibitory effect of 
quercetin upon tBOOH-induced changes in 14C-BT uptake 
correlated well with its inhibitory effect upon tBOOH-induced 
oxidative damage, as evaluated by quantification of lipid 
peroxidation.  
 
5. Conclusion 
Our results clearly show that oxidative stress decreases BT 
uptake by non-tumoral intestinal epithelial cells (Fig. 9). Given the 
important physiological role played by BT at the intestinal level, 
our results are indeed of major importance. Interaction of oxidative 
stress with BT transport is particularly important  in the context of 
carcinogenesis and inflammatory bowel disease. Indeed, oxidative 
stress is associated with initiation and progression of colon 
carcinogenesis and inflammatory bowel disease (Acharya et al., 
2010; Almenier et al., 2012; Seril et al., 2003), and is also involved 
in the link between chronic inflammation and cancer (Wiseman 
and Halliwell, 1996). BT has anticarcinogenic and 
antiinflammatory effect and reduces oxidative stress at the 
intestinal level (Hamer et al., 2008; Wong et al., 2006). So, given 
the protective role played by BT in the intestine, inhibition of BT 
intestinal epithelial uptake may contribute to the procarcinogenic 
and proinflammatory effect of oxidative stress at this level.  
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Figure 9. Effect  of oxidative stress (tBOOH 3000 µM) on BT transport in 
intestinal epithelial cells. MCT1 (monocarboxylate transporter 1, gene name 
SLC16A1) and SMCT1 (sodium-coupled monocarboxylate transporter 1, gene name 
SLC5A8) mediate influx of BT at the apical membrane. BCRP (gene name ABCG2) 
is an ATP dependent efflux transporter for BT at the apical membrane. O xidative 
stress inhibits SMCT1-mediated BT uptake and stimulates both uptake and efflux o f 
BT by passive diffusion. The inhibition of BT uptake is dependent on the generation 
of ROS by NADPH and xanthine oxidase, and on mitogen-activated protein kinase 
(MAPK) extracellular signal regulated kinase 1/2 (ERK 1/2) and protein tyrosine 
kinase (PTK) activation. 
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A - Characterization of BT transport at the intestinal epithelial level 
BT is an important metabolic substrate in normal colonic epithelial cells; however, 
colonic epithelial tumoral cells show a reduction in BT uptake (through a reduction in MCT1 
and SMCT1 protein expression) and glycolysis becomes their primary energy source [221,226]. 
So, knowledge on intestinal BT transport mechanisms and their regulation is crucial in the 
context of CRC pathophysiology. Moreover, BT presents an anticarcinogenic effect by 
induction of cell differentiation and apoptosis and by inhibition of proliferation, thus reducing 
the growth rate of many colon tumoral cells [56,57], and knowledge on this anticarcinogenic 
effect of BT led to a number of clinical trials testing its effectiveness as a potential tre atment 
for cancer. Because the effects of BT (e.g. inhibition of histone deacetylases) are dependent on 
its intracellular concentration, knowledge on the mechanisms involved in its membrane 
transport is therefore relevant to both its physiological and pharmacological benefits.  In this 
context, this study aimed at investigating the characteristics of the intestinal transport of BT, 
its regulation, and to search for implications of BT intestinal transport for CRC. Because in vivo 
studies performed with humans and laboratory animals are expensive, time -consuming and 
often even unethical (the three “Rs” paradigm), in vitro methods (as accurate as possible) offer 
a suitable alternative for in vivo testing. Primary colon cell cultures (isolated from human or 
animal tissue), are rarely used due to limitations with repeatability and long-term studies 
because of their short life span. So, in order to accomplish our objectives we studied the 
uptake of 14C-BT in several immortalized intestinal epithelial cell lines. The great advantage of 
using these cell lines as a model is their relative easiness and inexpensiveness of culture and 
maintenance; long-term viability, reproducibility and uniformity; together with the suitability 
to allow performance of qualitative and quantitative transport studies, facilitating the study of 
many compounds and conditions. The cellular models used in this study were the Caco-2 
human colonic adenocarcinoma cell line [254], and two nontransformed intestinal epithelial 
cell lines, the FHC fetal human colonic epithelial cell line [255] and the IEC-6 rat intestinal 
epithelial cell line [256]. We found important to compare BT transport in a colon 
adenocarcinoma cell line (Caco-2 cells) and in non-tumoral intestinal epithelial cell lines (FHC 
and IEC-6 cells) in the context of possible distinct BT transport mechanisms in these cells.  
Previous studies have shown that MCT1 is expressed in normal colonic epithelium, that 
uptake of the primary energy source for these cells, BT, is MCT1-mediated [138-140], and that 
MCT1 expression decreases in colonic transition from normality to malignancy [66]. However, 
we have demonstrated that MCT1 plays a major role in the apical uptake of BT in the Caco-2 
adenocarcinoma cell line, because  14C-BT uptake by this cell line was: (1) time- and 
concentration-dependent; (2) pH-dependent; (3) Na+-independent and Cl --dependent; (4) 
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energy-dependent; (5) inhibited by several BT structural analogues (acetate, propionate, α-
ketobutyrate, pyruvate, lactate); (6) insensitive to the anion exchange inhibitors DIDS and SITS 
and (7) inhibited by the MCT inhibitors NPPB and pCMB (I). This agrees with the fact that MCT1 
is highly expressed in these cells (I) [138,257]. So, 14C-BT uptake by Caco-2 cells is MCT1-
mediated (Figure 13) and this cell line may be utilized to study regulation of MCT1 expression 
and function (I). 
 
Figure 13. Proposed model  of expression and function of BT transporters  in the adenocarcinoma cell  line Caco -2. In 
colon tumoral  cells, glycolysis becomes the primary energy source, exceeding BT oxidative energetic metabolism 
[221,226], and cells rapidly convert the majori ty of glucose into lactate [258]. BT is a histone deacetylase inhibi tor 
promoting his tone acetylation. MCT1 (monocarboxylate transporter 1, gene name SLC16A1) mediates  influx of BT 
and may also mediate efflux of lactate at the apical  membrane. 
 
Tumoral cells convert the majority of glucose into lactate, and to maintain a permissive 
intracellular pH, high glycolytic rates and ATP levels, cells must efficiently export lactate [244]. 
MCTs are bidirectional transporters [147], and powerful regulators of the tumor intracellular 
pH by extruding lactate together with a proton [244]. Although MCT1 expression decreases 
during colonic transition from normality to malignancy (being downregulated in the early 
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stages of carcinogenesis) [66], some studies also described an MCT1 upregulation in advanced 
metastatic CRC tumors [189,246]. In these advanced CRC tumors, cells are highly glycolytic and 
upregulation of some isoforms of MCTs may occur as a means of exporting lactate. Because 
the adenocarcinoma cell line Caco-2 expresses minimal levels of MCT4 [257], lactate may be 
extruded by MCT1 (Figure 13). Interestingly, MCT1 inhibition decreases intracellular pH, 
resulting in tumoral cell death [190,250,259]. The anticarcinogenic effect of BT is believed to 
result from inhibition of histone deacetylases [69,70]. However, it is also interesting to 
speculate that MCT1-mediated BT uptake may decrease the intracellular pH, resulting in 
tumoral cell death. 
Studies have shown that SMCT1 expression is silenced in CRC and colon cancer cell 
lines, which may result in reduced uptake and metabolism of BT [67,201]. However, no studies 
have characterized SMCT1 function in the native human intestine, or in human nontumoral 
intestinal epithelial cell lines. So, we decided to characterize BT uptake by two nontransformed 
intestinal epithelial cell lines: the fetal human colonic epithelial (FHC) and the rat small 
intestinal epithelial (IEC-6) cell lines (II). The FHC cell line was found to express MCT1 but not 
SMCT1 mRNA. However, the characteristics of ¹⁴C-BT uptake by FHC cells ((1) energy-
independence; (2) pH-, Na+- and Cl−- independence and (3) insensitivity to BT structural 
analogues and MCT1 inhibitors) did not support either MCT1 or SMCT1 involvement in BT 
uptake. For this reason, FHC cells did not seem to be a good cell model to further investigate 
BT uptake (II). On the other hand, ¹⁴C-BT transport characteristics in IEC-6 cells were as follow: 
(1) time- and concentration-dependence; (2) pH-dependence; (3) Na+- and Cl−-dependence; (4) 
energy-dependence; (5) inhibition by BT structural analogues; (6) insensitivity to DIDS and 
amiloride; (7) sensitivity to MCT1 inhibitors (NPPB, pCMB and luteoline). Also, IEC-6 cells were 
found to express both MCT1 and SMCT1 mRNA. We thus conclude that 14C-BT uptake by IEC-6 
cells involves both MCT1 and SMCT1 (II). So, IEC-6 cells express a functional SMCT1 mediating 
BT absorption in a Na+-dependent manner, and this cell line may be utilized to study regulation 
of SMCT1 expression and function (II). Interestingly, more recent kinetic experiments revealed 
the existence of a high affinity and a low affinity transporter for 14C-BT in IEC-6 cells (VII), most 
probably corresponding to SMCT1 and MCT1, respectively (II) [139]. Physiologically, MCT1 is 
possibly more active in the proximal colon (Km of MCT1 is about 2.4–2.8 mM of BT (I)), where 
there is a high concentration of BT (in the mM range after digestion of dietary fiber) and the 
pH is lower [65]. Because SMCT1 has a low Km (50 µM), having a high affinity and low transport 
capacity for BT [260] and is more expressed in distal colon [193], SMCT1 is possibly more 
important in the distal colon (where there are lower concentrations of BT) [65]. However, 
DISCUSSION AND CONCLUSIONS 
161 
 
Smct1-null mice do not reveal a higher incidence of tumors in the colon [261], possibly 
because BT is also transported by MCT1 there [262]. 
BT cellular pools are not only dependent on the above BT uptake systems but also 
depend on efflux transporters, which are able to remove BT from the cells. The ATP-binding 
cassette (ABC) transporter superfamily includes membrane proteins that translocate a wide 
variety of substrates across membranes [263,264]. The human intestinal tract expresses high 
levels of some ABC transporters (e.g. P-glycoprotein (MDR1; encoded by ABCB1), multidrug 
resistance protein 1 (MRP1; encoded by ABCC1), and the breast cancer resistance protein 
(BCRP; encoded by ABCG2)), and these efflux transporters are believed to be involved in 
limiting drug absorption, bioavailability, and toxicity [263,264]. Because nothing was known 
concerning the putative interaction of BT with ABC transporter superfamily members, we 
decided to investigate the possibility of BT being transported by MDR1, MRPs or BCRP (III). 
Interestingly, we demonstrated that 14C-BT is a BCRP substrate and that inhibition of BCRP 
significantly potentiates the effect of BT on cell proliferation (III). BCRP derived its name as a 
result of its isolation from the drug resistant breast cancer cell line MCF-7/AdrVp [265]. 
However, BCRP is also expressed abundantly in several normal human tissues, including the 
apical membrane of normal intestinal and colonic epithelium [266]. So, we propose that in 
normal colon epithelial cells, BT is influxed by MCT1 and SMCT1 at the apical membrane ( II) 
[141,187] and, being the main energy source for colonocytes [53], is metabolized at the Krebs 
cycle. BT that is not metabolized is effluxed by BCRP, thus decreasing its intracellular 
concentration and so BT has no effect at HDACs levels (Figure 14). This is consistent with the 
fact that, in normal colonic tissue, BT does not inhibit cell proliferation [54,55,267-275]. 
BCRP expression is dramatically reduced in inflammatory bowel disease [276-278], 
which is interesting in the context of the relationship between inflammatory bowel disease 
and CRC, as cancer risk increases with the duration of inflammation [263]. Moreover, BCRP 
mRNA and protein expression is known to be significantly downregulated in human colorectal 
adenomas [263], in ApcMin mice (a mouse model of colon cancer) [263], in human CRC tissue 
and in most human cancers [279], suggesting that malignant transformation of the colonic 
epithelium in vivo is accompanied by a significant downregulation of BCRP. Studies also 
demonstrated that human BCRP polymorphisms (causing a decrease in its activity) could 
influence individual susceptibility to cancer [280,281]. Interestingly enough, BCRP exerts a 
protective function at the intestinal epithelial level by limiting the access of  dietary mutagens 
and carcinogens, such as heterocyclic amines (2-amino-1-methyl-6-phenylimidazo[4,5-
b]pyridine (PhIP) [282,283]; 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx), 2-amino-
3-methylimidazo[4,5-f]quinoline (IQ), 3-amino-1,4-dimethyl-5H-pyrido[4,3-b]indole (Trp-P-1) 
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[284]), polycyclic aromatic hydrocarbons (benzo[a]pyrene [285]), micotoxins (aflatoxin B1 
[286]), and sulfated and non-sulfated bile acids, to colonocytes [287]. So, a decrease in BCRP 
expression/function may place an individual at greater risk of exposure to 
dietary/environmental carcinogens. 
 
Figure 14. Proposed model of expression and function of BT transporters  and its  main intracellular targets  in 
colonocytes, including its  metabolism in the Krebs  cycle and i ts  effect on his tone acetylation.  Carriers  such as  MCT1 
(monocarboxylate transporter 1, gene name SLC16A1) and SMCT1 (sodium-coupled monocarboxylate transporter 1, 
gene name SLC5A8) mediate influx of BT at the apical  membrane. BCRP (gene name ABCG2) is an ATP-dependent 
efflux transporter for BT at the apical  membrane (I). At the basolateral  membrane, efflux of BT occurs  via  MCT4 
(monocarboxylate transporter 4, gene name SLC16A3). 
 
As described above, CRC is associated with a decrease in BCRP expression [279]. In 
accordance with this, in our study, the tumoral Caco-2 cells did not show BCRP-mediated efflux 
of BT (III). So, we hypothesize that, in these cells, BT will act as a histone deacetylase inhibitor 
(HDAC), leading to hyperacetylation of histones and to increased accessibility of transcription 
factors to DNA promoters [70], thus inducing apoptosis (V) [56,92], inhibiting proliferation and 
promoting a more differentiated phenotype (V) [93,94]. These apparent contradicting effects 
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of BT in normal colonocytes and in tumoral cells are often referred to as the ‘butyrate paradox’ 
[94]. Differences in metabolism and transport of BT between normal and tumoral cell s lines 
may contribute to this ‘butyrate paradox’ [288,289]. Based in our results, it is our opinion that 
the different levels of expression of BCRP in nontumoral and tumoral cells contributes to this 
paradox (V). 
As already mentioned, BT inhibits cellular proliferation and induces cellular 
differentiation and apoptosis of tumoral cell lines [93,94]. However, some cells overcome this 
effect of BT and become chemoresistant to this agent, as evidenced by the existence of BT-
resistant cell lines [270,290,291]. Given the anticarcinogenic effect of BT, identification of the 
mechanisms responsible for the acquisition of chemoresistance to this agent is of great 
potential value. As stated above, in our study, the tumoral cells (Caco-2) do not show BCRP-
mediated efflux of BT (III), which is in agreement with the low expression of BCRP in these cells 
[292,293]. However, in BT-treated (48h) Caco-2 cells, BCRP expression appears to increase and 
resulted in BCRP-mediated efflux of BT (III). This effect of BT in inducing BCRP expression was 
previously verified with another BCRP substrate (imatinib) in this same cell line [294]. 
Moreover, some other histone deacetylase inhibitors (phenylbutyrate, valproate, trichostatin 
A, suberoylanilide hydroxamic acid, depsipeptide and romidepsin) also increase BCRP 
expression in cancer cell lines [295-297]. So, histone modifications are likely associated with 
drug-induced BCRP overexpression in cancer cells [296]. We thus suggest that the increase in 
BCRP expression levels in response to BT is involved in the acquisition of chemoresistance to 
BT in tumoral cell lines [270,290,291]. 
As stated above, CRC is associated with a downregulation of BCRP expression, at least 
in the early stages of carcinogenesis [279]. However, some studies described BCRP 
overexpression in colorectal invasive cancers (i.e., advanced stage of carcinogenesis) [298-
300], suggesting that BCRP may be involved in cancer progression and metastasis. Numerous 
studies have also shown that BCRP is overexpressed in solid tumors [301]. Most solid tumors 
are exposed to low oxygen environments and BCRP gene transcription is activated by binding 
of HIF-1α to a hypoxia response element under low oxygen conditions [302]. Of note, BCRP is 
overexpressed in cancer cell lines and tumors that are “multidrug resistant” (MDR) (reviews by 
[303]). The term “multidrug resistance” (MDR) is used to describe the ability of cells exposed 
to a single drug to develop resistance to a broad range of structurally and functionally 
unrelated drugs [304]. BCRP is one of the human ABC transporters that have been implicated 
in MDR in cancer chemotherapy [305,306]. BCRP recognizes and transports numerous 
anticancer drugs including conventional chemotherapeutic and relatively new molecules in 
clinical use: 5-fluorouracil, methotrexate, mitoxantrone, anthracyclines, daunorubicin, 
DISCUSSION AND CONCLUSIONS 
164 
 
doxorubicin, topotecan, diflomotecan, irinotecan, tyrosine kinase inhibitors (eg. imatinib and 
gefitinib) and nucleoside analogs [307-309]. Thus, downregulation of BCRP expression and/or 
function has been proposed as part of a regimen to improve cancer therapeutic efficacy. BCRP 
inhibitors can accelerate the endocytosis and degradation of BCRP in lysosomes [310,311]. 
Several specific inhibitors of BCRP have been reported, and some are currently undergoing 
clinical trials or are available to treat patients [301]. It is interesting to speculate that BT, by 
competing with anticancer agents for BCRP, can increase their intracellular level, thereby 
increasing their cytotoxicity. So, interaction of BT with BCRP and with other BCRP 
substrates/inhibitors is indeed of major importance [307-309], and the combination of BT and 
anticancer agents that are BCRP substrates might have clinical implications for CRC therapy 
[312]. 
Tumoral cells convert the majority of glucose into lactate, and to maintain a permissive 
intracellular pH, cells must efficiently export lactate [244]. So, as a consequence of a high rate 
of lactate production in tumors, the extracellular pH is more acidic (5.8) that in normal tissues 
(7.5) [313]. Curiously, BCRP is overexpressed in tumors exposed to acidic environment [298-
300] and BCRP-mediated transport increases at acidic pH [314,315]. Because lactate is 
chemically related to BT and uses the same influx transporters [155,156], it would be 
interesting to evaluate if lactate is also effluxed by BCRP. Disruption of lactate transporters is 
one strategy for targeting tumoral cell metabolism [250-252], and if lactate is effluxed by 
BCRP, then inhibition of this transporter may be a promising target for anticancer strategy. 
 
B - Modulation of BT transport and of its anticarcinogenic effect 
Because BT plays a central role in colonic cellular metabolism and maintenance of 
tissue homeostasis, and because many cellular effects of BT are dependent on its intracellular 
concentration (e.g., inhibition of histone deacetylases), knowledge of the regulation of its 
absorption by the colon mucosa seems particularly important. Some studies have associated 
the intake of some mineral waters with reduced risk for CRC [316-318]. So, we decided to 
investigate the relationship between some mineral waters and 14C-BT uptake by Caco-2 cells. 
Both acutely and chronically, the sodium-bicarbonate-fluorate-carbonic water (Vidago®) 
increased MCT1-mediated uptake of 14C-BT (IV). Moreover, chronically, the bicarbonate-
fluorate-carbonic water (Melgaço®) also increased MCT1-mediated uptake of 14C-BT (IV). 
These results, showing that chronic exposure to Melgaço® and Vidago® water increases 14C-BT 
uptake, suggests that chronic ingestion of these waters can have a protective role against CRC 
by increasing the intestinal epithelial uptake of BT (IV). Interestingly, Melgaço® water increases 
14C-BT uptake while simultaneously decreasing 3H-O-methyl-glucose uptake (IV). The effect of 
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natural mineral waters upon 14C-BT uptake is obviously dependent on their mineral content. 
Importantly, these mineral waters are rich in Ca2+ or Mg2+, and some studies describe a 
protective effect of these minerals against CRC [319-321].  
Coffee and tea consumption is associated with a lower incidence of CRC [322-324]. So, 
we decided to evaluate the effect of two xanthines present in these beverages, caffeine and 
theophylline, on 14C-BT uptake (I, II). In Caco-2 cells, acute exposure to these xanthines 
reduced 14C-BT (10 μM) uptake (I). So, we concluded that caffeine and theophylline are MCT1 
inhibitors. However, chronic exposure to caffeine increased 14C-BT uptake. The increase in 14C-
BT uptake is not related to changes in MCT1 gene expression level, but most probably results 
from an increase in MCT1 activity (I). Interestingly, caffeine increased 14C-BT uptake while 
simultaneously decreasing Caco-2 cellular viability (I). However, in IEC-6 cells, caffeine was 
devoid of effect upon 14C-BT uptake (II). Because BT uptake in Caco-2 and IEC-6 cells is MCT1-
mediated and both MCT1 and SMCT1-mediated, respectively, these results suggest that acute 
caffeine inhibits MCT1 and has no effect upon SMCT1. 
High intake of dietary fiber is associated with a reduced risk of CRC [45-48]. However, 
protective effects of fiber-containing food subgroups (e.g. fruits and vegetables) can also be 
contributed by the presence of other nutrients such as phytochemicals (plant secondary 
metabolites). Phytochemicals have reported anticarcinogenic effects in various in vitro and in 
vivo models, and have a potential chemopreventive role in CRC development [325]. BT 
(produced by fermentation of dietary fiber) and phytochemicals are both present in the colon 
and may directly or indirectly influence each other’s actions. So, we decided to investigate the 
relationship between phytochemicals and 14C-BT uptake by Caco-2 cells (MCT1-mediated) (V) 
and IEC-6 cells (MCT1 and SMCT1-mediated) (II). Phytochemicals consist of over four 
thousands of naturally occurring substances [325]. We focused our attention in studying the 
effects of some of the most abundant phytochemicals present in non-alcoholic (tea) and 
alcoholic (beer, red wine) beverages, as well as in several fruit and vegetables: catechin, 
epicatechin, epigallocatechin-3-gallate (EGCG), xanthohumol, resveratrol, quercetin, rutin, 
chrysin and myricetin. 
Acutely (23 min), catechin, epicatechin and xanthohumol caused small but significant 
increases in 14C-BT (10 μM) uptake by Caco-2 cells (MCT1-mediated) (V). On the contrary, 
some other phytochemicals (e.g. resveratrol, quercetin, myricetin and chrysin) inhibited 14C-BT 
(10 μM) uptake (V). These phytochemicals were also tested against uptake of a high 
concentration of 14C-BT (20 mM). We verified that resveratrol, quercetin, myricetin, chrysin, 
EGCG, and epicatechin, at least in some of the concentrations tested, were able to significantly 
reduce uptake of high concentration of 14C-BT. For most of the compounds, the inhibitory 
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effect was not very pronounced, but resveratrol (100 μM) was able to cause a 30% reduction 
in 14C-BT uptake. Resveratrol behaved as a competitive inhibitor of MCT1, since it reduced the 
transporter affinity for 14C-BT (increased its Km), without affecting its Vmax (V). Resveratrol and 
quercetin also inhibited 14C-BT uptake in IEC-6 cells (MCT1 and SMCT1-mediated), but 
myricetin and chrysin were devoid of effect (II). Because BT uptake in Caco-2 and IEC-6 cells is 
MCT1-mediated and both MCT1 and SMCT1-mediated, respectively, these results suggest that, 
acutely, resveratrol and quercetin do also inhibit SMCT1-mediated BT uptake and that 
myricetin and chrysin have no effect on this transporter. 
However, when chronically tested (48h), some phytochemicals (e.g. quercetin, EGCG, 
rutin, chrysin, myricetin and catechin) were able to significantly increase 14C-BT (20 mM) 
uptake by Caco-2 cells (V). Importantly, the increase in 14C-BT uptake correlated with an 
increase in MCT1 mRNA expression levels for catechin (0.1 µM) and chrysin, suggesting that 
their effect upon 14C-BT uptake results from changes in MCT1 transcription rates (V). As for 
quercetin, EGCG, rutin and myricetin, they probably change protein levels or the intrinsic 
transporter activity (V). This increase in 14C-BT uptake might be involved in the 
anticarcinogenic effect of at least some of these phytochemicals (V). However, chrysin, 
myricetin and EGCG were devoid of effect when tested chronically, and resveratrol and 
quercetin even inhibited 14C-BT uptake in IEC-6 cells, which was not associated with changes in 
MCT1 or SMCT1 transcription levels (II). So, the chronic effect of phytochemicals is 
dramatically different in Caco-2 and IEC-6 cells. Our general conclusion is that, chronically, 
phytochemicals increase 14C-BT uptake (thus increasing its intracellular concentration) in 
tumoral cells (Caco-2), and have no effect or even inhibit 14C-BT uptake in normal cells (IEC-6). 
These results are very interesting in the context of different effects of phytochemicals in 
tumoral and nontumoral cells. 
In Caco-2 cells, BT (5 mM; 48h) markedly decreased cellular viability and proliferation 
and increased cell differentiation and apoptosis (V). Moreover, EGCG, quercetin, chrysin and 
rutin had no effect on cellular viability but significantly increased apoptosis (6–10x) (V). Also, 
EGCG, quercetin and chrysin showed antiproliferative effects at low concentrations (0.1-1 µM), 
but they presented a proproliferative effect when tested in higher concentration (10 µM) ( V). 
The antiproliferative effect of EGCG, quercetin and chrysin may be associated with a decrease 
in 14C-BT oxidation (by 13–15%) (V). Moreover, rutin decreased cell differentiation (V). We 
then investigated if some of these phytochemicals could interfere with the effects of BT upon 
cellular viability, proliferation, differentiation and apoptosis, and we verified that combination 
of these compounds with BT did not significantly modify the effects of BT ( V). The lack of 
modulation of BT effects by phytochemicals might have two explanations: (1) chronic 
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treatment (48h) with BT (5 mM) upregulates MCT1 [158,168-170] and also MCT4 and its 
chaperone CD147 [326], and this increase in MCT-mediated transport maximizes BT uptake 
that is thus no further enhanced by phytochemicals; (2) chronically, phytochemicals such as 
quercetin and chrysin are known to increase the expression of efflux transporters such as BCRP 
[285,327]. So, besides increasing BT uptake by the cells, phytochemicals may also have caused 
an increase in its efflux (III), thus having no significant effect on its intracellular concentrations. 
Nonsteroidal anti-inflammatory drugs (NSAIDs) emerged as a new perspective in 
tumor therapy as well as in cancer prevention [328,329]. Interestingly, uptake of some NSAIDs 
is in part mediated by MCT1 [330,331]. So, we decided to evaluate the effect of two NSAIDS, 
acetylsalicylic acid and indomethacin, on 14C-BT uptake (I, II). In Caco-2 cells, acute exposure to 
acetylsalicylic acid and indomethacin concentration-dependently inhibited 14C-BT uptake, and 
so we conclude that these two compounds are inhibitors of MCT1-mediated transport of BT (I). 
However, acetylsalicylic acid showed a very unusual effect, as it simultaneously increased the 
Km and the Vmax  of 
14C-BT uptake, thus appearing to cause a decrease in the affinity while 
increasing the capacity of MCT1 for BT (I). In IEC-6 cells, indomethacin also inhibited 14C-BT 
uptake (even more potently that in Caco-2 cells), but acetylsalicylic acid was devoid of effect 
(II). Because BT uptake in Caco-2 and IEC-6 cells is MCT1-mediated and both MCT1 and SMCT1-
mediated, respectively, these results suggest that indomethacin also inhibits SMCT1-mediated 
uptake and that, on the contrary, acetylsalicylic acid has no effect upon this transporter. 
Ethanol is the most frequently used drug worldwide [332]. Epidemiological data have 
identified chronic alcohol consumption as a significant risk factor for CRC [333,334]. Although 
ethanol is not carcinogenic in animal models, its bacterial fermentation in the colon produces 
acetaldehyde, which is highly toxic, mutagenic and carcinogenic, and the main responsible for 
alcohol-associated carcinogenesis [335,336]. Ethanol is oxidized to acetaldehyde by alcohol 
dehydrogenase (ADH) present in intestinal bacteria and colonocytes, and then to acetate by 
aldehyde dehydrogenase (ALDH) in the liver. Of note, ADH activity is significantly higher in CRC 
tissues than in healthy tissues leading to the accumulation of acetaldehyde in CRC tissues after 
ingestion of ethanol [337]. Most of the acetaldehyde generated during alcohol metabolism in 
vivo is promptly eliminated by ALDH2 [338]. Interestingly, approximately 40% of Japanese, 
Koreans or Chinese carry a mutant allele in the ALDH2 gene (ALDH2*2) [338,339]. This allele 
codes for an enzyme with little activity, thus leading to high acetaldehyde concentrations after 
the consumption of even small amounts of alcohol [339]. When individuals with this allele 
chronically consume ethanol, a significant increased risk for CRC is noted [339-341]. Cigarette 
smoking has also been suggested to be one of the risk factors for CRC [13,342]. Nicotine, one 
of the major components of cigarette smoking, can stimulate cell proliferation and suppress 
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apoptosis of colon cancer cells [343-346]. Cocaine also enhances tumor growth [347,348]. On 
the other hand, amphetamine decreases tumors in animal models [349,350], and Δ-9-
tetrahydrocannabinol (THC) shows antitumoral effects [351]. Because the above mentioned 
substances (ethanol, acetaldehyde, nicotine, Δ-9-tetrahydrocannabinol (THC), cocaine, 
amphetamine and ecstasy (3,4-methylenedioxymethamphetamine, MDMA)) may have a direct 
effect in CRC, we decided to investigate their effect upon 14C-BT uptake. We verified that 
acutely, ethanol in IEC-6 cells (II) and acetaldehyde in Caco-2 and IEC-6 cells (I, II) inhibited 14C-
BT uptake in a concentration-dependent manner. From these results, we can speculate that 
interference with 14C-BT uptake in the colonic epithelium might contribute to the CRC 
promoter effect of ethanol and acetaldehyde, associated with the consumption of alcoholic 
beverages. Of the others drugs of abuse tested, only THC and MDMA (48h) decreased 14C-BT 
uptake and the expression level of MCT1 (by 20–30%) (I). So, we conclude that interference 
with BT uptake does not seem to be the main mechanism involved in the effect of these 
compounds upon tumor growth. 
High dietary fat is associated with increased CRC risk; however, it should be noted that 
the type of fat is also important. A growing body of experimental, epidemiological and clinical 
evidence supports the contention that bioactive food components containing n−3 long chain 
polyunsaturated fatty acids (PUFAs) (e.g., eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA)) decrease CRC incidence [352,353], and that the opposite effect is observed with n-
6 PUFAs (e.g., linoleic acid (LA) and arachidonic acid (AA)) [354,355]. For this reason, we 
decided to investigate the effect of n-3 PUFAs (DHA and EPA), n-6 PUFAs (LA, γ-linolenic acid 
and AA), and conjugated linoleic acid (CLA) upon 14C-BT uptake in tumoral (Caco-2) and non-
tumoral (IEC-6) intestinal epithelial cell lines (VI). We observed only a discrete interference of 
n-3 and n-6 PUFAs and CLA with the apical uptake of 14C-BT. So, we conclude that interference 
with the uptake of BT does not seem to be one of the mechanisms involved in the recognized 
role that these compounds have in colon carcinogenesis. The antitumoral activity associated 
with n−3 polyunsaturated fatty acids may depend more on (1) modulation of COX-2 activity; 
(2) alteration of membrane dynamics and cell surface receptor function, and (3) increased 
cellular oxidative stress levels [356]. 
A possible mechanism that associates dietary fat with increased CRC risk is the 
production of bile acids for solubilization and absorption of dietary lipids in the gut [357]. 
Several epidemiological, animal and in vitro studies correlate secondary bile acids with CRC 
[358]. In relation to primary bile acids, less information is available. However, the primary bile 
salt chenodeoxycholic acid (CDCA) was shown to be tumour promoting in some animal and cell 
culture studies [359,360] and a significantly higher faecal concentration of CDCA was seen in 
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patients with CRC/adenoma [361]. CDCA concentrations up to 700–800 μM have been 
reported in fecal waters [362,363], suggesting high concentrations in colon. So, we decided to 
investigate the effect of CDCA upon 14C-BT uptake in tumoral (Caco-2) and non-tumoral (IEC-6) 
intestinal epithelial cell lines. We demonstrated that chronically, CDCA markedly and 
concentration-dependently inhibits 14C-BT uptake by IEC-6 cells (IC50 = 120 µM) and, less 
potently, by Caco-2 cells (IC50 = 402 µM) (VII). Moreover, the results suggest that CDCA inhibits 
both MCT1 and SMCT1 (Figure 15), although the inhibitory effect of CDCA is more pronounced 
for SMCT1 than for MCT1 (VII).  
 
Figure 15. Effect of chenodeoxycholic acid (CDCA) in BT transport in intestinal epi thelial cells. MCT1 
(monocarboxylate transporter 1, gene name SLC16A1) and SMCT1 (sodium-coupled monocarboxylate transporter 1, 
gene name SLC5A8) mediate influx of BT at the apical membrane. CDCA inhibi ts both MCT1 and SMCT1-mediated 
BT transport. Inhibi tion of BT uptake by CDCA is dependent on CaM, PKC, and MAP kinase (ERK1/2 and p38 
pathways) activation and reduced by a  reactive oxygen species  scavenger. 
 
Furthermore, CDCA reduces the effect of BT on cell viability and differentiation (VII), 
suggesting that inhibition of BT uptake by CDCA causes a lower intracellular concentration of 
this agent and less inhibition of HDACs. Moreover, inhibition of BT uptake by CDCA is 
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dependent on Ca2+/calmodulin (CaM), mitogen-activated protein kinases (extracellular signal 
regulated kinase 1/2 (ERK 1/2) and p38 pathways) and protein kinase C (PKC) activation and is 
reduced by a reactive oxygen species (ROS) scavenger (VII). This last result suggests that bile 
acids-generated ROS [364,365] are involved in inhibition of 14C-BT uptake by CDCA. 
The gastrointestinal tract is a major target for oxidative stress damage due to constant 
exposure of ROS generated by a large variety of xenobiotics, the intestinal flora, and 
endogenous substances (e.g. bile acids) [366]. Also, production of ROS is a possible mechanism 
involved in alcohol-related carcinogenesis [367]. So, we decided to investigate the effect of 
oxidative stress upon BT uptake at the intestinal epithelial level. We chose to use IEC-6 cells 
because these are normal intestinal epithelial cells, and typically normal cells have persistently 
lower levels of ROS than tumor cells and are more sensitive to ROS [368]. IEC-6 cells were 
submitted to treatment with tert-butylhydroperoxide 3000 µM (tBOOH), which increased 
levels of oxidative stress biomarkers, while maintaining cellular viability. We demonstrated 
that oxidative stress inhibited SMCT1- mediated 14C-BT transport, but not MCT1-mediated 14C-
BT uptake; moreover, it increases uptake and efflux of BT by passive diffusion (Figure 16) (VIII). 
Inhibition of SMCT1-mediated BT uptake by tBOOH is dependent on mitogen-activated protein 
kinase (MAPK) extracellular signal regulated kinase 1/2 (ERK 1/2) and protein tyrosine kinase 
(PTK) activation and on the generation of ROS by NADPH and xanthine oxidase  (VIII). 
Interestingly enough, the phytochemicals quercetin and resveratrol partially prevented the 
effect of oxidative stress upon 14C-BT uptake (VIII). Quercetin and resveratrol are known to 
have strong antioxidant activities, due to their ability to directly scavenge ROS and to modulate 
expression of antioxidant enzymes [325]. Quercetin is also known to inhibit xanthine oxidase 
(which appears to be activated by tBOOH) [369]. Quercetin completely abolished the increase 
in lipid peroxidation caused by tBOOH (VIII). So, treatment with these phytochemicals possibly 
reduced cellular oxidative stress levels and thus protected the structure and function of BT 
transporters. Knowing that tumor cells are under increased ROS and ROS-induced oxidative 
stress compared to normal cells [370,371], and that oxidative stress inhibits 14C-BT uptake 
(VIII) we can speculate that: (1) the absence of SMCT1-mediated 14C-BT uptake observed in 
tumoral intestinal epithelial cells (Caco-2 cells) may be related to the increased oxidative stress 
levels found in these cells [370,371]; and (2) the increase in 14C-BT uptake in Caco-2 cells found 
after chronic treatment (48h) with some phytochemicals (quercetin, EGCG, rutin, chrysin, 
myricetin and catechin) (V) is possibly related to their antioxidant properties (and consequent 
reduction in oxidative stress) [370,371]. 
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Figure 16. Effect of oxidative stress (tBOOH 3000 µM) on BT transport in intestinal epi thelial cells. MCT1 
(monocarboxylate transporter 1, gene name SLC16A1) and SMCT1 (sodium-coupled monocarboxylate transporter 1, 
gene name SLC5A8) mediate influx of BT at the apical  membrane. BCRP (gene name ABCG2) is an ATP dependent 
efflux transporter for BT at the api cal  membrane. Oxidative s tress  inhibi ts  SMCT1-mediated BT uptake and 
s timulates both uptake and efflux of BT by passive di ffusion. The inhibi tion of BT uptake is dependent on the 
generation of ROS by NADPH and xanthine oxidase, and on mitogen-activated protein kinase (MAPK) extracellular 
signal  regulated kinase 1/2 (ERK 1/2) and protein tyrosine kinase (PTK) activation. 
 
Altogether, from the analysis of the above discussed results, two important 
experimental remarks arise. First, the observation that BT uptake and modulation in Caco-2 
and IEC-6 cells are functionally different, these cell lines being good models to study MCT1- 
and SMCT1-mediated intestinal BT transport and function, respectively. Second, the 
observation that acute and chronic treatment of the cells with diverse xenobiotics did not 
produce parallel results and this should be taken into account when speculating about acute 
effects from chronic effects and vice versa. Curiously, some xenobiotics have opposite effects 
when tested acutely or chronically. For example, acutely, xanthines (caffeine and theophylline) 
(I), some phytochemicals (resveratrol, quercetin, myricetin and chrysin) (V) and NSAIDs 
(acetylsalicylic acid and indomethacin) (I) are inhibitors of MCT1-mediated BT uptake. 
However, chronic exposure (48h) to these compounds did not change (theophylline, 
resveratrol, acetylsalicylic acid and indomethacin) or even increased (caffeine, quercetin, 
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myricetin, chrysin, rutin, EGCG, catechin) 14C-BT uptake. This increase in 14C-BT uptake might 
be involved in the chronic anticarcinogenic effect of these compounds. However, the chronic 
increase in 14C-BT uptake observed with these compounds is not related to changes in MCT1 
expression because most of compounds have no effect or even decreased the MCT1 
expression level (I, V).  
As mentioned, one of the proposed beneficial effects of BT on human intestinal health 
is the prevention of colon carcinogenesis. Therefore, compounds that acutely decrease 14C-BT 
uptake into intestinal epithelial cells are potentially detrimental to intestinal health and 
integrity. Nevertheless, in CRC tumors, glycolysis becomes the primary energy source and 
these compounds possibly also inhibit lactate release mediated by MCT1 with a consequent 
inhibition of glycolysis (II; V) [181-183]. So, we can speculate the inhibition of tumoral 
metabolism (i.e. glycolysis) is a mechanism accounting for their acute anticarcinogenic effects. 
Interestingly enough, some compounds described as acutely inhibiting MCTs have been 
pointed out as chemopreventive agents (e.g. BT, phytochemicals, NSAIDS, cholesterol 
synthesis inhibitors and lonidamine) [372-376]. Three very interesting cases of MCT1 inhibition 
and inhibition of glycolysis are exemplified below: 1) BT, which is transported by MCT1 (I), but 
is also known to decrease glucose uptake, glycolysis, glutaminolysis and lactate secretion 
[273,377,378]; 2) the phytochemical resveratrol, which is a competitive inhibitor of MCT1 (V), 
but is also described as a glucose uptake inhibitor [379], and was shown to decrease glycolysis 
in tumoral cells [380]; and 3) acetylsalicylic acid, which is an MCT1 inhibitor (I), and was shown 
to decrease glycolysis and lactate secretion in tumoral cells [381-383]. 
 
 
C  - Cancer cell metabolism 
The natural plant cannabinoid, Δ-9-tetrahydrocannabinol (THC), was recognized in 
1975 as a potential anticancer agent [384]. Since then, there has been a great effort to 
investigate the therapeutic potential of cannabinoids in various types of cancer [385] and a 
first human clinical study has been performed in 2006 [351]. At the intestinal level, 
cannabinoid compounds show antitumoral effect by decreasing viability, proliferation, 
adhesion and migration in a variety of colorectal cancer cell lines (SW480, HCT-15, HT29, Caco-
2, HCT116, LS174T and SW620 cells), as well as by modulating angiogenesis and metastasis 
[386,387]. 
A common feature of all cancers is their increased dependence on glucose as a 
preferred source for energy and biosynthesis [388]. So, colon tumoral cells show an increase in 
the rate of glucose uptake (glucose transporters, e.g. GLUT1) and glycolysis (the Warburg 
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effect) [221,224,225]. Accordingly, ample evidence indicates that cancer cells are more 
sensitive to glucose deprivation than normal cells [252,389,390]. Because THC has the ability 
to inhibit glucose uptake at testis, brain and placenta level [391-394], we decided to evaluate 
the effect of some cannabinoid agonists (THC, anandamide, CP55,940) and antagonists 
(AM251, AM630) on 3H-2-deoxy-D-glucose (3H-DG) uptake by the tumoral Caco-2 cells. 2-
deoxy-D-glucose is a glucose analogue efficiently transported by facilitative glucose 
transporters (e.g. GLUT1) [395]. We verified that cannabinoid agonists had no effect in 3H-DG 
uptake (IX). Acutely, the cannabinoid THC had also no effect in 14C-BT uptake by Caco-2 cells 
(I), although chronic THC decreased 14C-BT uptake and the expression level of MCT1 (by 30%) 
(I). So, we conclude that interference with the uptake of glucose and BT does not seem to be 
one of the mechanisms involved in the recognized role that cannabinoids have in colon 
carcinogenesis. 
Clotrimazole (CTZ) shows anticarcinogenic activity in colon tumoral cells lines 
[396,397], associated with its ability to inhibit glycolysis and ATP production because it causes 
detachment of glycolytic enzymes from cytoskeleton [398]. We decided to investigate the 
anticarcinogenic effect of CTZ in a tumoral intestinal epithelial (Caco-2) cell line, to compare it 
with the effect in a nontumoral intestinal epithelial cell line (IEC-6 cells), and to investigate 
inhibition of energy substrate (glucose and BT) uptake as a mechanism contributing to it. In 
both Caco-2 and IEC-6 cells, CTZ (20 μΜ) caused a similar decrease in cell viability  and 
proliferation (X). So, the anticarcinogenic potential of CTZ at the intestinal epithelial level may 
be compromised by the fact that this compound exhibits comparable cytotoxic effects in both 
tumoral and nontumoral intestinal epithelial cell lines. Exposure of Caco-2 cells to CTZ 
increased (by 20-30%) the uptake of glucose analogs (3H-DG and 3H-OMG) but had no effect on 
14C-BT uptake (X). We suggest that the increase in the uptake of glucose analogs in the 
presence of CTZ constitute a compensatory cellular mechanism in response to inhibition of 
glycolysis caused by this agent, and we also suggest that the inhibitory effect of CTZ in relation 
to glycolysis can be potentiated by a reduction in glucose availability through inhibition of its 
uptake (e.g. with phytochemicals that are able to effectively reduce glucose uptake and show 
anticancer properties [399-402]). Interestingly enough, combination of CTZ with 
rhodamine123 was found to significantly reduce Caco-2 cell viability and to cause a more 
pronounced decrease in cellular proliferation, in relation to CTZ or rhodamine123 alone (X). 
So, the cytotoxic effect of clotrimazole was strongly potentiated by inhibition of oxidative 
phosphorylation. Taken together, these results suggest that glycolysis may not be the rate 
limiting pathway for ATP production in Caco-2 cells, because oxidative phosphorylation is also 
active in these cells. Indeed, a growing number of studies have shown that mitochondria in 
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tumor cells are not inactive per se but operate at low capacity and produce ATP [403]. Also, in 
situations of glucose limitation, tumor cells can adapt to survive by using exclusively an 
oxidative energy substrate [404,405]. So, tumors show an enhanced glycolytic flux; however, 
not all have a diminished mitochondrial metabolic capacity. In conclusion, glycolysis and 
oxidative phosphorylation cooperate to sustain energy needs for Caco-2 cells [406]. 
Interestingly, glycolysis inhibition is particularly effective in those cells that present 
mitochondrial defects and rely most for their ATP production on this metabolic pathway [407], 
and targeting mitochondria might be a promising strategy to increase the sensitivity of tumor 
cells to apoptotic mechanisms [408]. So, administration of a drug that inhibits glycolysis (e.g. 
clotrimazole, tamoxifen, imatinib, cisplatin) in conjunction with an inhibitor of oxidative 
phosphorylation (e.g. 5-fluorouracil, taxol, diclofenac, sulindac) may be useful for treating 
colon tumors that have both active glycolysis and oxidative phosphorylation [408-410]. Other 
promising strategy is the use of compounds that simultaneously inhibit glycolysis and oxidative 
phosphorylation, e. g. 3-bromopyruvate [242] or resveratrol [379,411,412]. 
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The final concluding remarks of this thesis are listed below. 
 
 
 
With respect to the characterization of BT transport at the intestinal epithelial level: 
 
(1) In the tumoral intestinal epithelial cell line (Caco-2 cells), 14C-BT uptake is MCT1-mediated 
and this cell line may be used to study regulation of MCT1 expression and function. 
 
(2) In the non-tumoral intestinal epithelial cell line (IEC-6 cells), 14C-BT uptake is both MCT1 
and SMCT1-mediated and this cell line may be used to study regulation of SMCT1 expression 
and function. 
 
(3) BT is a breast cancer resistance protein (BCRP) substrate, and inhibition of BCRP 
significantly potentiates the effect of BT on cell proliferation. 
 
 
 
With respect of the modulation of BT transport and of its anticarcinogenic effect: 
 
(1) Acutely (23 min), MCT1 activity is inhibited by acetaldehyde, caffeine, theophylline, 
tetrahydrocannabinol and MDMA (ecstasy), by some phytochemicals (e.g. resveratrol, 
quercetin, myricetin and chrysin), and NSAIDs (acetylsalicylic acid and indomethacin), and is 
increased by some other phytochemicals (e.g. catechin, epicatechin and xanthohumol). 
 
(2) Chronically (48h), MCT1 activity is increased by caffeine, quercetin, myricetin, chrysin, 
rutin, EGCG and catechin, and is inhibited by CDCA. SMCT1 activity is inhibited by CDCA and by 
oxidative stress. 
 
(3) The expression of MCT1 mRNA is regulated by exposure to certain xenobiotics. Namely, it is 
decreased by EGCG, myricetin, and catechin, caffeine, tetrahydrocannabinol, MDMA (ecstasy), 
and increased by chrysin. SMCT1 mRNA expression is increased by CDCA. 
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(4) BT (5 mM; 48h) markedly decreased cellular viability and proliferation and increased cell 
differentiation and apoptosis of the tumoral intestinal epithelial cell line (Caco-2 cells). 
 
(5) EGCG, quercetin, chrysin and rutin had no effect in cellular viability but significantly 
increased apoptosis (6–10x) of Caco-2 cells. EGCG, quercetin and chrysin showed 
antiproliferative effects at low concentrations (0.1-1 µM). 
 
(6) Chronically (48h), EGCG, quercetin, chrysin and rutin increased 14C-BT uptake in Caco-2 
cells. However, combination of these compounds with BT did not significantly modify the 
effects of BT in cellular viability, proliferation, differentiation and apoptosis. 
 
(7) CDCA inhibits both MCT1 and SMCT1-mediated 14C-BT uptake and reduces the effect of BT 
on cell viability and differentiation of IEC-6 cells. 
 
(8) Oxidative stress (tBOOH 3000 µM) inhibits SMCT1-mediated 14C-BT uptake and stimulates 
both uptake and efflux of 14C-BT by passive diffusion in IEC-6 cells. 
 
 
 
With respect of cancer cell metabolism: 
 
(1) Cannabinoid agonists have no effect in glucose uptake. 
 
(2) In both Caco-2 and IEC-6 cells, clotrimazole (CTZ) caused a similar decrease in cell viability 
and proliferation. However, CTZ increased (by 20-30%) the uptake of glucose analogs (3H-DG 
and 3H-OMG) but had no effect on 14C-BT uptake in Caco-2 cells. 
 
(3) Glycolysis may not be the rate limiting pathway for ATP production in Caco-2 cells, because 
oxidative phosphorylation is also active in these cells. 
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With respect of the physiological implications of our results: 
 
(1) SMCT1 is silenced in the tumoral intestinal epithelial Caco-2 cell line. 
 
(2) Differences in BCRP expression between normal colonocytes and tumoral cells may 
contribute to different effects of BT in these cells (‘the butyrate paradox’). 
 
(3) Interaction of BT with BCRP and with other BCRP substrates/inhibitors is of major 
importance, and the combination of BT and anticancer agents that are BCRP substrates might 
have clinical implications for CRC therapy. 
 
(4) Administration of drugs that inhibit glycolysis (e.g. clotrimazole, tamoxifen, imatinib, 
cisplatin) in conjunction with an inhibitor of oxidative phosphorylation (e.g. 5-fluorouracil, 
taxol, diclofenac, sulindac) may be useful for treating colon tumors that have both active 
glycolysis and oxidative phosphorylation. 
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We believe that the conclusions attained with this work contribute to a more profound 
knowledge on the mechanisms of BT intestinal transport and its modulation by diverse 
endobiotics and xenobiotics, its relationship to the anticarcinogenic effect of this compound 
and with CRC. As ever, in scientific research, much work remains to be done. In the near 
future, it would be interesting to evaluate in vivo (by using a rat model) the effect of some 
compounds/conditions that modulate BT uptake (e.g. ethanol, acetaldehyde, CDCA, oxidative 
stress) on the protective effects of BT against CRC [60,413]. Because we found BT to be a BCRP 
substrate, and BCRP acts as an efflux transporter for various anticancer agents (5-fluorouracil, 
methotrexate, mitoxantrone, anthracyclines, daunorubicin, doxorubicin, topotecan, 
diflomotecan, irinotecan, nucleoside analogs and tyrosine kinase inhibitors), and thus decrease 
their cytotoxic effects, the combination of BT and these anticancer agents might have clinical 
implications for CRC therapy. So, it would be very interesting to test this hypothesis in nude 
mice with tumor cells implanted in the colon [312]. 
Interestingly, tumoral colon cells convert the majority of glucose into lactate, and in 
order to avoid intracellular acidification and death, these cells must export protons [414].  
Several systems are adapted for the transport of protons, among which MCTs should be 
considered candidates for pHi regulation and promising targets for anticancer strategies [251]. 
AZD3965, an orally administered compound related to AR-C117977 (a specific MCT1 inhibitor 
[415,416]) is currently entering Phase I/II clinical trials for advanced solid tumors therapy 
(http://science.cancerresearchuk.org/). However, systemic delivery of MCTs (and more 
specifically MCT1) inhibitors could affect almost every organ of the body, with the most drastic 
effects on cardiac and skeletal muscle (fatigue and toxicity) [417], and causing also inhibition of 
lymphocyte proliferation [184]. Also, silencing or pharmacological inhibition of MCT1 in colon 
cancer cells has been shown to be effective only in the absence of MCT4 expression, indicating 
functional redundancy of MCT1 and MCT4 [418]. However, no specific MCT4 small molecule 
inhibitor has been identified so far [415]. Because BT inhibits both transporters (MCT1 and 
MCT4) and is well metabolized, having no side effects [417], we think this molecule is a good 
compound to test in the context of inhibition of lactate release and glycolysis in CRC [419]. 
Interestingly, treatment of colon cancer cells with BT decreased glucose uptake, glycolysis, 
glutaminolysis and lactate secretion [273,377,378]. 
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Butyrate (BT) is the main energy source for normal colonic epithelial cells and inhibits 
colon carcinogenesis (by suppressing growth of cancer cells, inducing differentiation and 
apoptosis and inhibiting cell proliferation). Studies suggest that BT is transported into colonic 
epithelial cells by the H+-coupled monocarboxylate transporter 1 (MCT1) and by the Na+-
coupled monocarboxylate cotransporter 1 (SMCT1). However, colonic epithelial tumoral cells 
show a reduction in BT uptake, by lowering MCT1 and SMCT1 protein expression, and 
glycolysis becomes the primary energy source of these cells. So, knowledge on intestinal BT 
transport mechanisms and its regulation is crucial in the context of colorectal cancer (CRC) 
pathophysiology and of the physiological and pharmacological effects of BT. In this context, 
our objectives were to investigate the characteristics of intestinal transport of BT in the human 
colonic adenocarcinoma cell line Caco-2 and in two nontransformed intestinal epithelial cell 
lines, the fetal human colonic epithelial cell line FHC and the rat intestinal epithelial cell line 
IEC-6. We found important to compare BT transport in a colon adenocarcinoma cell line (Caco-
2) and in non-tumoral intestinal epithelial cell lines (FHC, IEC-6) in the context of possible 
distinct BT transport mechanisms and regulation in these cells. Knowing that xenobiotics and 
endobiotics can modulate the risk for developing CRC, we aimed at studying regulation of BT 
transport mechanisms by these compounds. Finally, we also aimed at studying if some of  the 
xenobiotics and endobiotics shown to interfere with BT transport would interfere with the 
anticarcinogenic effect of BT and if this effect can contribute to the anticarcinogenic or 
procarcinogenic effect of these compounds. 
Our results led us to conclude that: 1) BT uptake by Caco-2 cells is MCT1-mediated; 2) 
BT uptake by FHC cells is neither MCT1 nor SMCT1-mediated; 3) BT uptake by IEC-6 cells is 
MCT1 and SMCT1-mediated; 4) BT is a substrate for the efflux transporter breast cancer 
resistance protein (BCRP), and inhibition of BCRP significantly potentiates the effect of BT on 
IEC-6 cell proliferation; 5) the tumor cells (Caco-2) do not show BCRP-mediated efflux of BT, 
but in BT-treated Caco-2 cells, BCRP-mediated efflux of BT was found. In relation to 
modulation of BT transport, we could conclude that BT transport is modulated by several 
chemically unrelated endo and xenobiotics, either after acute or chronic exposure. This may 
have important implications for CRC. For example, the decrease in BT uptake observed with 
ethanol, acetaldehyde, the primary bile salt chenodeoxycholic acid and with tert-
butylhydroperoxide (oxidative stress inducer) and the increase in BT uptake found with 
caffeine and some phytochemicals (polyphenols) correlates well with their effects upon CRC. 
We also observed that the anticarcinogenic compound clotrimazole (CTZ), a glycolysis 
inhibitor, increases glucose uptake but does not affect BT uptake. So, the anticarcinogenic 
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effect of CTZ can be potentiated by a reduction in glucose availability through inhibition of its 
uptake. 
We believe that these conclusions contribute to a more profound knowledge on the 
mechanisms of BT intestinal transport, its modulation by xenobiotics and endobiotics, and on 
the relationship between BT transport at the intestinal epithelial level and CRC. 
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O butirato (BT) é a fonte de energia principal para as células epiteliais do cólon 
normais e inibe a carcinogénese ao nível do cólon (pela supressão do crescimento das células 
tumorais, indução da diferenciação e apoptose e inibição da proliferação celular). Vários 
estudos sugerem que o BT é transportado para as células epiteliais do cólon pelo 
transportador de monocarboxilatos acoplado a H+ do tipo 1 (MCT1) e pelo transportador de 
monocarboxilatos acoplado ao Na+ do tipo 1 (SMCT1). No entanto, as células epiteliais 
colónicas tumorais apresentam uma redução na captação de BT (baixando a expressão 
proteica de MCT1 e SMCT1) e a glicólise torna-se a fonte de energia primária destas células. 
Assim, o conhecimento sobre os mecanismos de transporte intestinal de BT e a sua regulação 
é fundamental no contexto da fisiopatologia do cancro coloretal (CCR), e no contexto dos 
efeitos fisiológicos e farmacológicos do BT. Neste contexto, os nossos objetivos foram 
investigar as características de transporte intestinal de BT na linha celular de adenocarcinoma 
de cólon humano (células Caco-2) e em duas linhas celulares epiteliais intestinais não 
transformadas, a linha celular de epitélio fetal de colon humano (células FHC) e a linha celular 
de epitélio de intestino de rato (células IEC-6). A comparação entre o transporte de BT numa 
linha celular de adenocarcinoma de cólon humano (Caco-2) e em linhas celulares epiteliais 
intestinais não-tumorais (FHC, IEC-6) pareceu-nos importante no contexto de possíveis 
mecanismos distintos de transporte de BT e sua regulação nestas células. Sabendo-se que 
vários xenobióticos e endobióticos podem modular o risco para o desenvolvimento de CCR, 
tivemos também como objetivo estudar a possível interferência de alguns desses compostos 
com o transporte de BT. Finalmente, também foi nosso objetivo estudar como é que a 
interferência no transporte de BT pode contribuir para o efeito anti-carcinogénico ou pró-
carcinógenos destes compostos. 
Os nossos resultados levaram-nos a concluir que: 1) a captação de BT pelas células 
Caco-2 é mediada pelo MCT1; 2) a captação de BT pelas células de FHC não é mediada nem 
pelo MCT1 nem pelo SMCT1; 3) a captação de BT pelas células IEC-6 é mediada pelo MCT1 e 
pelo SMCT1; 4) o BT é substrato do transportador de efluxo proteína de resistência ao cancro 
da mama (BCRP), e a inibição da BCRP potencia significativamente o efeito do BT sobre a 
proliferação celular das células IEC-6; 5) as células tumorais (Caco-2) não mostram efluxo de BT 
mediado pela BCRP, mas em células Caco-2 tratadas com BT observa-se efluxo de BT mediado 
pela BCRP. Em relação à modulação do transporte de BT, podemos concluir que o transporte 
de BT é modulado por vários endo e xenobióticos não relacionados quimicamente, após uma 
exposição aguda ou crónica. Isto pode ter importantes implicações para o CCR. Por exemplo, a 
diminuição na captação de BT observada com o etanol, acetaldeído, o sal biliar primário ácido 
quenodesoxicólico e com o tert-butilhidroperóxido (um indutor de stresse oxidativo), e o 
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aumento na captação de BT encontrado com a cafeína e alguns fitoquímicos (polifenóis) 
correlaciona-se com o efeito destes compostos sobre o CCR. Também observamos que o 
composto anticarcinogénico clotrimazole (CTZ), inibidor da glicólise, aumenta a captação de 
glicose mas não afeta a captação de BT. Assim, o efeito anticarcinogénico do CTZ pode ser 
potenciado por uma redução na disponibilidade de glucose através da inibição da sua 
captação. 
Acreditamos que estas conclusões contribuem para um conhecimento mais profundo 
sobre os mecanismos de transporte intestinal de BT, sua modulação por xenobióticos e 
endobióticos, bem como sobre a relação entre o transporte de BT a nível intestinal e o CCR. 
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